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A simple and efficient radical C-H functionalization to access modified cyclodextrins (CDs) has 
been developed. The well-defined conformation of glycosidic and aglyconic bonds in D-, E-, and 
J-CDs favors the intramolecular 1,8-hydrogen atom transfer (HAT) promoted by the 6I-O-yl radical 
which abstracts regioselectively the hydrogen at C5II of the contiguous pyranose. The C5II-radical 
evolves by a polar crossover mechanism to a stable 1,3,5-trioxocane ring between two adjacent 
2 
 
glucoses or alternatively triggers the inversion of one D-D-glucose into a 5-C-acetoxy-E-L-idose 
unit possessing a 1C4 conformation. The 6I,IV- and 6I,III-diols of D- and E-CDs behave similarly to 
the monoalcohols, forming mostly compounds originating from two 1,8-HAT consecutive 
processes. In the case of 6I,II-diols the proximity of the two 6-O-yl radicals in adjacent sugar units 
allows the formation of unique lactone rings within the CD framework via a 1,8-HAT±E-scission 
tandem mechanism. X-Ray diffraction carried out on the crystalline 1,4-bis(trioxocane)-D-CD 
derivative shows a severe distortion toward a narrower elliptical shape for the primary face. 
INTRODUCTION 
Over the past decades, cyclodextrins (CDs) have been extensively investigated for their valuable 
applications in several areas.1 These naturally-occurring cyclic oligosaccharides are composed of 
glucose units in 4C1 chair conformations, with a hydrogen bond network formed between the 
secondary hydroxyl groups, creating a conical shape with an internal hydrophobic cavity, 
conferring the ability to form host-guest or inclusion complexes with a great variety of molecules 
and rendering them one of the most important supramolecular host families. Because of these 
inclusion properties, CDs are displayed as being potentially useful as drug and gene delivery 
systems,2 artificial enzymes3 or catalysts,4 just to cite a few. 
Considering their unique features and relevant applications, great effort has been invested in 
developing chemical modifications of native CDs to modulate their chemophysical properties, and 
thus achieve an enhancement of their solubility, a change in their cavity size or an improvement in 
their inclusion capability. The strategies are usually based on grafting a wide assortment of 
substituents taking into account the different accessibility and reactivity of the hydroxyl groups to 
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obtain diverse patterns of functionalization, which act as platforms to access amphiphilic CDs,5 
and hence, sophisticated molecular architectures.6 
It should be pointed out that most of these methodologies have addressed the structural changes 
retaining the 4C1 chair conformation of the glucose units, but a few of them describe modifications 
of the cavity by altering the conformations of these units. Thus, the reported synthesis of 3,6-
anhydro-CDs shows the conformational change of the pyranose units to 1C4, and consequently, a 
significant change in their binding properties.7 Moreover, the formation of a mono-2,3-epoxide-E-
CD followed by a nucleophilic ring opening generates an altrose unit in a 1C4 which distorts the 
cavity from conical to elliptical.8 The introduction of several altrose moieties reflects a rapid 
equilibrium between 1C4 and 4C1 conformers and their ratio depends on the number of residues and 
their position in the macromolecule.9 The cycloglycosylation syntheses of cyclodextrin analogues 
composed exclusively of L-sugars or incorporating both L- and D-sugars residues have been 
reported.7a Finally, it has been found that in the crystalline structure of permethylated E-CD one of 
the D-glucose residues is inverted from the normal 4C1 to the 1C4 chair conformation.10 
Interestingly, in the methodologies employed to create this structural diversity in CDs, regardless 
of conformational changes, radical reactions are practically unknown and this fact is not surprising 
if we consider that in simple carbohydrates they mainly involve the anomeric position which is 
committed in the cyclic CD structure.11 Only one example has been reported in the literature and 
is focused on the intermolecular attack of reactive-oxygen-centered free radicals on CDs in aqueous 
solution using EPR detection experiments.12  
During the last several years, our group has been immersed in the development of methods for the 
DFWLYDWLRQ DQG IXQFWLRQDOL]DWLRQ RI ³LQHUW´ C±H bonds in carbohydrate chemistry.13 Of special 
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interest is a novel 1,8-hydrogen atom transfer reaction (1,8-HAT) which takes place, through a 
rather unusual nine-membered transition state (TS), between both pyranose units in a Hexp-ĺ-
Hexp disaccharide system. The hydrogen abstraction at C5II is promoted, in a highly regioselective 
manner, by the electrophilic 6I-O-yl radical I generated from the corresponding alcohol under 
oxidative conditions, producing a C5II radical II (Scheme 1).  
Scheme 1. Radical polar crossover mechanism for the HAT reaction promoted by 6-O-yl 
radicals in Hexp-(1ĺ4)-Hexp systems of carbohydrates. DIB = (diacetoxyiodo)benzene. 
 
This intermediate suffers a one-electron oxidation causing a crossover from the radical to the 
oxacarbenium ion III which is subsequently trapped by the alcohol to give the intramolecular 
bridged eight-membered 1,3,5-trioxocane IV. The obtained results show that this regioselectivity 
is highly dependent on both the four stereogenic centers implicated in the cyclization step (C5II, 
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C1II, C4I, and C5I) as the conformation of the glycosidic () = H1II±C1II±O4I±C4I) and aglyconic 
(< = C1II±O4I±C4I±H4I) bonds. In fact, when these stereochemical and conformational requisites 
are not suitable for the 1,8-HAT to take place, the alkoxyl radical I may alternatively abstract the 
hydrogen at C1II via a 1,6-HAT to produce a new C1II radical V which, after oxidation to the 
respective oxacarbenium ion VI and cyclization, gives the spiro ortho ester VII. 
For the E-maltose disaccharide, D-D-Glcp-ĺ-E-D-Glcp, the reaction proceed with complete 
regioselectivity, yielding compounds formed exclusively from the 1,8-HAT.13a In this case, the 
corresponding glycosidic and aglyconic bonds in the TS involved () = ±32.7, < = ±37.3o) are 
arranged in an exo-syn conformation, where the alkoxyl radical and the H5II are at an optimal 
distance of 3.1 Å for the initial abstraction step.14 
With this result in mind, we decided to investigate whether this radical-polar crossover 
methodology could be extended to more complex carbohydrates such as CDs, since in these 
systems the D-glucose units are linked in a similar fashion (cyclo-[D-D-Glcp-ĺ@n). The 
measures of distances and angles made on the reported X-ray structure of permethylated E-CD15 
as well as on its minimized structure indicate that there is sufficient inter-residue flexibility in the 
macromolecule to adopt an exo-syn conformation similar to E-maltose. Therefore, from a 
theoretical point of view, the 1,8-HAT process could take place between two vicinal units of the 
macrosystem to provide modified CDs on their primary face, which could exhibit important 
distortions in their cavities.  
Preliminary results of this work have been described recently and we now present here the full 





RESULTS AND DISCUSSIONS 
Initially, the most common and readily available E-cyclodextrin was the substrate of choice in order 
to investigate the viability of this radical process. The corresponding monoalcohol 2I-VII,3I-VII,6II-
VII
-icosa-O-methyl-E-CD (1) necessary to assay the reaction was prepared from the commercial E-
CD following a well-known three-step sequence consisting in monosilylation of one primary 
alcohol, O-methylation of the remaining hydroxyl groups and finally removal of silyl-ether.17 This 
protocol has the advantage of using methyl ethers as protecting groups which usually allow an 
increase in solubility both in water and in organic solvent.18 To our delight, visible light irradiation 
of alcohol 1 with diacetoxyiodobenzene (DIB) (2.2 equiv) and iodine (1 equiv) at 30 oC proceeded 
nicely in 30 minutes delivering the expected 1,3,5-trioxocane 2 (36%) and the acetate 3 (61%) as 
the major compound (Table 1, entry 1).19 Lower reaction temperatures or fewer equivalents of 
reagents (DIB or I2) only gave rise to slower and incomplete reactions while the increase in the 
reaction times or the amount of reagents allowed us to obtain exclusively trioxocane 2 in 60% yield 
(entry 2). The reaction is plausibly explained by a sequential intermolecular nucleophilic attack by 
acetate anion to give 3 followed by an intramolecular cyclization leading to 2. A competitive 
addition of both nucleophiles to the oxacarbenium ion intermediate may also be considered.20 
Obviously, both products, 2 and 3, derived from the same C5VII radical intermediate, through an 
intramolecular 1,8-HAT reaction promoted by the 6I-O-yl radical. No compounds resulting from 
abstraction at C1VII via a 1,6-HAT process were detected. 
In both compounds, the oxidation at C5VII was clearly confirmed by 1D and 2D NMR experiments. 
Thus, for compound 2, the HMBC correlation of the H1VII proton signal at GH 5.06 ppm with the 
C5VII quaternary carbon atom (GC 101.04 ppm) corroborates this C5VII functionalization. Moreover, 
7 
 
all D-glucopyranose units are preferentially in 4C1 chair conformations as we can be deduced from 
the values of the coupling constants of the anomeric hydrogens (3J1,2 §+] 
 
Table 1. 1,8-HAT for 6I-ol-E-CD 1, 6I-ol-D-CD 5, and 6I-ol-J-CD 8.a 
 
entry substrate I(III)/I2 (equiv) products (yield) 
1 1; E-CD DIB/I2 (2.2/1.0) 2 (36%) 3; R = Ac (61%) 
2 1; E-CD DIB/I2 (3.0/1.7) 2 (60%) ± 
3 1; E-CD PhI(OCOAd)2/I2 (2.2/1.0)b No reaction 
4 1; E-CD PhI(OCO-2,4,6-iPr3Ph)2/I2 (2.2/1.0) No reaction 
5 1; E-CD PhI(OCO-4-tBuPh)2/I2 (2.2/1.0) 2 (46%) n.d. 
6 1; E-CD PhI(OCO-2,4,6-Me3Ph)2/I2 (2.2/1.0) 2 (21%) 4; R = CO-2,4,6-Me3Ph (33%) 
7 5; D-CD DIB/I2 (2.2/0.5) 6 (31%) 7; R = Ac (30%) 
8 5; D-CD DIB/I2 (2.2/1.0) 6 (59%) ± 
9 8; J-CD DIB/I2 (2.2/0.5) 9 (36%) 10; R = Ac (41%) 
10 8; J-CD DIB/I2 (2.2/1.0) 9 (44%) ± 
aReaction conditions: A solution of the alcohol in dry CH2Cl2 containing the organoiodine(III) reagent and I2 was stirred under 
nitrogen while irradiated with two 80 W tungsten-filament lamps. n.d. = not determined. b Ad = 1-Adamantyl. 
 
With respect to the acetyl derivative 3, the deshielding observed for the ring protons of the unit VII 
bearing the acetyl group and the magnitude of the 3JH,H coupling constants [3J1,2 = 1.9 Hz (calcd 
1.3 Hz), 3J2,3 = 2.5 Hz (calcd 2.6 Hz), and 3J3,4 = 1.9 Hz (calcd 3.3 Hz)] suggest that the ring exists 
substantially in a 1C4 inverted chair conformation.21 Moreover, the NOE experiment shows an 
interaction between H1VII and the acetyl methyl protons, thus tentatively establishing the 
stereochemistry at C5VII as R. These data indicate that the acetate group has been incorporated with 
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inversion of configuration at C5VII and consequently the original D-D-glucopyranose has been 
transformed into a 5-C-acetoxy-E-L-idopyranose unit,22 flipping from 4C1 to 1C4 chair 
conformation. As far as we know, this is the first precedent of a E-CD molecule having a E-L-idose 
unit in its structure. Conversely, in the formation of trioxocane 2, the intramolecular nucleophilic 
addition to the oxacarbenium ion occurs with retention of configuration at C5VII or by a double 
inversion if we consider 3 to be an intermediate. 
To achieve additional insight into the incorporation of acetate, we decided to explore the reaction 
with different bis(acyloxyl) hypervalent iodine(III) reagents to evaluate the nucleophilic addition 
of other acyloxyl groups to the C5 position.23 As depicted in Table 1, in the cases of the sterically 
demanding 1-adamantylcarboxyl (entry 3) or 2,4,6-triisopropylbenzoyloxyl (entry 4), the reaction 
did not proceed, recovering most of the unchanged starting material in both cases. This may be 
caused by the steric hindrance of the acyl hypoiodite intermediate which precludes entirely the 
formation of the 6I-O-yl radical.24 When the ester was the 4-tert-butylbenzoyloxyl (entry 5), TLC 
analysis showed the completion of the reaction and the presence of two main products. However 
after chromatographic separation we were able to isolate only the cyclized compound 2 in 46% 
yield, presumably due to intramolecular hydrolytic cleavage of the ester. Only the reaction with 
bis(2,4,6-trimethylbenzoyloxy)iodobenzene allowed us to isolate both products, 2 and 4, albeit in 
moderate yield, 21% and 33% respectively, together with a significant amount of starting material 
(39%) (entry 6). The NMR data for 4 show clearly that, also in this case, the ring chair conformation 
of unit VII has been inverted. 
The effectiveness of this methodology was tested on D- and J-CD models. The corresponding 
monoalcohols 525 and 826 were prepared following the same three-step protocol employed for the 
6I-ol-E-CD derivative 1. Using similar amounts of DIB and iodine, both substrates behaved in an 
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analogous manner to the E-CD case, generating the corresponding trioxocane derivatives 6 and 9 
and acetates 7 and 10, albeit in somewhat lower overall yields (Table 1, entries 7(?10). While the 
trioxocane derivatives are stable for long periods of time at room temperature and can be easily 
manipulated, the acetates seem to be acid- and base-sensitive compounds. The use of an excess of 
iodine (entries 8 and 10), aqueous work up or standard silica gel column chromatographic 
purification preclude their isolation and the reaction gives exclusively the respective trioxocane 
derivatives 6 and 9 in variable yields. Fortunately, pure acetates 7 and 10 could be obtained using 
0.5 equiv of iodine, avoiding any work up and after careful flash chromatography employing silica 
gel scraped from commercially coated TLC plates (entries 7 and 9). 
As described above for the E-CD derivative 3, the structures and conformations of the acetyl 
derivatives 7 and 10 were corroborated by 1D TOCSY and 2D HSQC and HMBC experiments. 
Remarkably, the conformation of unit VI of compound 7 exhibits changes in the TOCSY 
experiments by varying from CDCl3 to C6D6. The observed values of the coupling constants of this 
unit in CDCl3 [3J1,2 = 2.8 Hz (calcd 1.4 Hz), 3J2,3 = 3.2 Hz (calcd 2.5 Hz), and 3J3,4 = 2.8 Hz (calcd 
3.3 Hz)] indicate predominantly a 1C4 conformation while in C6D6 these values [3J1,2 = 3.5 Hz 
(calcd 3.2 Hz), 3J2,3 = 8.5 Hz (calcd 9.7 Hz), and 3J3,4 = 7.9 Hz (calcd 9.2 Hz)] preferentially point 
to a 4C1 conformation.21 In contrast, the acetates 3, 4, and 10, derived from E- and J-CD, show the 
same 1C4 conformation in both solvents. The inversion barrier seems to be significantly lower in 
the more strained hexameric ring. 
Encouraged by these promising results with mono-alcohols, we decided to investigate what would 
happen in this HAT process if we have two primary hydroxyl groups in the molecule which can 
react simultaneously, a situation hitherto little studied.27 Taking into account the structure of E- and 
D-CDs, there are three different positional isomers (6I,II-, 6I,III-, and 6I,IV-diol) for each of them. 
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With the aim of obtaining cyclized compounds, we examined the relative stability of the expected 
final products, the 1,4-, 1,3-, and 1,2-bis(1,3,5-trioxocane) compounds. A preliminary analysis 
using molecular mechanic calculations revealed that the energetic differences among the three 
isomers, in either E- or D-CD, are very small (approx. 2 kcal/mol), providing evidence for the 
thermodynamic feasibility of the cyclization step.28 
Therefore, we decided to synthesize the three isomeric diols of each CD using a similar protection-
deprotection sequence employed for the monoalcohols, as has been described previously,17a and 
assess the scope of this methodology. 
The study was begun with the more distant 1,4-diol derivatives, that we believe have greater 
possibilities of success. Firstly, we carried out the reaction of the 6I,IV-diol-E-CD derivative 1117a 
with DIB and I2 as shown in Scheme 2. Gratifyingly, the process proceeded in good overall yield, 
affording the 1,4-bis(trioxocane) 12 (20%), the diacetate 13 (49%) as the main product, and a 3:2 
chromatographically inseparable mixture of mono-trioxocane±mono-acetyl positional isomers 
(14%, not shown, see the Experimental Section) which could be transformed into 12 after treatment 
with iodine. Analogously, compound 12 was obtained when 13 was submitted to these iodine 
catalyzed conditions. The acetyl methyl protons at C5III and C5VII in compound 13 were readily 
assigned by 2D HSQC and HMBC experiments, whereas the 1H NMR showed the deshielding of 
the ring protons in these units III and VII and the values of their coupling constants (3JH,H §±
2.5 Hz) were consistent with the introduction of both acetates with inversion at C5 and thus, with 
the presence of two E-L-idose units in 1C4 conformations. Although no chair inversion was detected 
using C6D6 as solvent, the axial H1III and H1VII protons started to broaden at 18 oC suggesting that 
coalescence is just below this temperature, while the signals were sharpened by heating at 70 oC. 
Additionally, the stereochemistry of the quaternary centers C5III and C5VII were established 
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tentatively as R on the basis of NOE interactions between H1III or H1VII and the respective acetyl 
methyl protons. 
Scheme 2. 1,8-HAT for the 6I,IV-diol-E-CD 11 and 6I,IV-diol-D-CD 14 
 
Next, we explored the behavior of 6I,IV-diol-D-CD derivative 1425,29 under these oxidative radical 
conditions. The reaction afforded the bis- and mono-trioxocanes 15 and 16 as sole compounds, not 
detecting any product from incorporation of acetate into the molecule, and thus, revealing the 
greater steric hindrance in this hexamer (Scheme 2). Moreover, compound 15 is a crystalline solid 
whose structure was unambiguously confirmed by X-ray crystallographic analysis, showing two 
trioxocane rings in a restricted boat-chair (BC) conformation with a guest n-hexane molecule in 
the CD cavity (Figure 1).30 The simplified 1H and 13C NMR spectra are consistent with the C2 
symmetry of the proposed structure. 
The comparison of the geometrical structural parameters of 15 with those of the related 
permethylated D-CD31 shows that the presence of the two 1,3,5-trioxocane rings severely distort 
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the primary face of the molecule. This distortion is clearly observed when comparing the 
geometrical parameters of the irregular hexagon comprising the side-chain carbon atoms (C6n), 
which points toward a much narrower elliptical shape for this rim (see Tables S2 and S3 in the 
Supporting Information). Conversely, the presence of the bis(trioxocane) rings does not 
significantly alter the secondary face of the molecule. Thus, for instance, the distances and angles 
between the six interglycosidic oxygen atoms (O4n), as well as the radii of the gravity center of the 
hexagon formed by these O4n oxygen atoms are quite similar in both X-ray structures. The most 
significant differences are observed in the tilt angles made by the O4n mean plane and the mean 
planes through the glucose units principally in residues II and V adjacent to the trioxocane rings. 
What do not seem to be affected either are the 4C1 chair geometries of the six glucose units, as 
shown by the Cremer±Pople puckering parameters which describe slightly distorted chairs similar 
to those found in the permethylated D-CD (see Tables S2 and S3).32 
 
Figure 1. X-ray crystal structure of 15. C blue, O red, 1,3,5-trioxocane ring yellow-green, H atoms 




Scheme 3. HAT for the 6I,III-diol-E-CD 17 
 
We next focused our attention on applying the C±H functionalization to 1,3-diol derivatives. The 
reaction of 6I,III-diol-E-CD 1717a under the usual conditions produced one compound derived from 
the mono-abstraction, the acetate 18 in 21% yield together with four compounds in 47% overall 
yield arising from double abstraction: the diacetate 19 with incorporation of two external 
nucleophiles, the two possible mono-trioxocane±mono-acetyl derivatives 20 and 21, and the spiro 
ortho ester±trioxocane 22 in which only internal nucleophiles are implicated (Scheme 3). 
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Curiously, the expected bis(trioxocane) was not detected in the crude reaction mixture, even after 
longer reaction times. 
Analogously, the incorporation of the acetate has taken place with inversion at C5 and 
transformation of the sugar into a E-L-idose unit. This appears to be a general trend for all 
compounds even in the cases of compounds 13 and 19 where two units in a 1C4 inverted chair 
conformation exist as part of the heptameric ring. 
On the other hand, the positional isomers 20 and 21 can be differentiated by a careful study using 
2D HSQC and HMBC and 1D TOCSY and ROESY experiments. The H1I and H4II 1D ROESY 
correlation that has been observed in both compounds can be used to distinguish between both 
isomers. The H4II protons, that have been clearly identified by 1D TOCSY, appear at 3.90 ppm (d, 
3J3II,4II = 9.0 Hz) for compound 20 and at somewhat lower field 4.11 ppm (d, 3J3II,4II = 2.9 Hz) for 
the isomer 21, which undoubtedly confirms the proposed structures. 
Moreover, in compound 22 where two positional isomers could be a priori possible we were able 
to assign the correct structure, since the 1D ROESY experiment showed a correlation between H1III 
and H4IV [(3.60 ppm (dd, J = 9.2, 9.2 Hz)]. In the other hypothetical isomer (spiro ortho ester at 
unit I and trioxocane at unit III) the analogous ROESY interaction would have been between H1I 
and H4II near the trioxocane and this last proton should be a doublet. Although two stereoisomers 
at the spiro quaternary carbon at C1II are possible, only one has been isolated and the configuration 
tentatively assigned as R. Molecular mechanics calculations show that the R-isomer is more stable 
by 6 kcal/mol than the S-isomer. The stereochemistry is supposed to be stereoelectronically 
controlled, in the R-isomer the alcohol approaches the oxacarbenium ion by the D-axial direction 
to maximize the anomeric effect.33 Additional support was secured by examination of the 1H NMR 
spectrum, revealing a downfield displacement for the pro-S H6III proton [4.24 (dd, J = 9.1, 7.9 
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Hz)], which in this stereoisomer presents a 1,3-diaxial interaction with the C1II±OII bond. An 
obvious experiment that could be important for the determination of this stereochemistry such as 
the study of NOE correlations from H2II could not be performed due to signal overlap. Fortunately, 
this problem does not exist in the 1H NMR spectrum of the analogous spiro ortho ester 30 and the 
results confirm the proposed stereochemistry (vide infra). 
In contrast with the previous results, when the reaction is performed with the hitherto unknown 
6I,III-diol-D-CD 23, we only obtained the bis- and the two possible mono-trioxocanes 24, 25 and 26 
respectively, in 66% overall yield, not detecting products with inverted E-L-idose units in the 
molecule (Scheme 4). This is in agreement with the results obtained in the 6I,IV-diol series where 
we did not find inverted sugar units in the reaction of 6I,IV-diol-D-CD 14 (Scheme 2). 




Although, all structures were analogously determined by NMR spectroscopy the preparation of the 
acetyl derivatives 27 and 28 from both mono-trioxocanes was necessary to differentiate these 
positional isomers. The NOE interaction between H1I and H4II [4.26 ppm (d, J = 9.2 Hz)] in 
compound 27 and the corresponding correlation between H4VI and H1V [5.04 ppm (d, J = 3.2 Hz)] 
in the isomer 28 firmly stablished the proposed structures. 
Finally, to complete the study of the diols, the reactions of 1,2-diols of E- and D-CDs were carried 
out. The reaction of the 6I,II-diol-E-CD 2917a under the usual oxidative conditions led to the 
formation of four compounds in moderate overall yield: the spiro ortho ester±trioxocane 30 (5%), 
the ten-membered lactone 31 (10%) and a mixture of two products, 32 and 33, which after 
acetylation was readily separated as the mono-trioxocane 34 and the G-lactone 35, in 22% and 11% 
yield respectively (Scheme 5). The relative position of the spiro ortho ester with respect to the 
trioxocane rings in 30 and the primary acetate with respect to the trioxocane in 34 was readily 
established by spectroscopic means. The ring coupling constants for the sugar units involved were 
determined by 1D TOCSY and ROESY experiments but in any case, the alternative structures for 
the positional isomers should have a very different 1H and 13C NMR pattern. The spiro quaternary 
carbon stereochemistry C1I in compound 30 was assigned as R on the basis discussed above for 
analogous spiro ortho ester 22. The absence of NOE interactions between H2I and the pro-S H6II, 
which was expected for the S-isomer, provides additional support for the anomeric configuration 
as R. 
The ten-membered lactone 31 possesses a one-carbon dehomologated skeleton and among its more 
important structural and functional features are: the presence of carboxyl and acetal functions and 
the disappearance of one of the anomeric carbons of the starting E-CD. The protons of the sugar 
residues I and II can be differentiated by 1D TOCSY and all the above appears to confirm the 
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decanolide structure proposed, while additional support is provided by HMBC 1,3-correlations, 
being of special significance that observed between the carboxyl carbon at C5I and the two protons 
at H6II. 
Scheme 5. HAT for the 6I,II-diol-E-CD 29 
 
The G-lactone 35 has also a one carbon dehomologated skeleton and the more notable features of 
its structure are the large deshielding observed for the chemical shift of the anomeric hydrogen at 
HI [5.56 ppm (d, J = 3.2 Hz)] and the 1,3-HMBC correlation of this proton with the carboxylic 
carbon at C5I. 
According to these results, the formation of all products described in Scheme 5 could be explained 
in terms of which of the two primary alkoxyl radicals (6I-O-yl or 6II-O-yl) is generated first. In this 
sense, compound 30 should be formed by the 6I-O-yl radical 1,8-abstraction in the first place 
followed by a second 1,6-abstraction of the 6II-O-yl radical to generate the spiro ortho ester. 
Clearly, the primary alcohol 32 should be an intermediate in the formation of 30. On the other 
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hand, the mechanism for the formation of lactones 31 and 33 from diol 29 certainly implies a prior 
abstraction of hydrogen at H5I by the 6II-O-yl radical to give the trioxocane VIII (Scheme 6). The 
excess of reagent generates a new 6I-O-yl radical from the free primary alcohol which by E-scission 
with loss of formaldehyde produces a C5I tertiary radical IX.34 This intermediate evolves following 
two competitive paths: (i) it may experience a second E-scission of the C1I±OI bond leading to the 
C1I-radical X, which by one-electron oxidation and nucleophilic attack by the acetate anion finally 
gives the ten-membered lactone 31 and (ii) it can be directly stabilized by oxidation±nucleophilic 
attack to give the G-lactone 33 previous hydrolysis of ortho ester intermediate XI. Neither 
intermediate VIII nor XI could be detected in the crude reaction mixture. 
Scheme 6. Proposed mechanistic pathway for the formation of lactones 31 and 33 
 
Analogously to the E-CD derivative, the C±H functionalization of the 6I,II-diol-D-CD 3635 
proceeded in a similar way, giving the corresponding ten-membered lactone 37, the mono-
trioxocane 38 and the G-lactone 39 in 51% overall yield (Scheme 7). All these compounds show 
NMR features similar to those of the respective compounds 31, 34 and 35 and their formation can 
be explained by a mechanism identical with that described for the E-CD model (Scheme 6). 
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Although, as commented previously, the formation of the 1,2-bis(trioxocane)s in D- and E-CDs 
may be thermodynamically possible, we have been unable to detect any of them. Therefore, the 
possibility of a second 1,8-HAT on the logical precursors, the isolated mono-trioxocanes 32 and 
38, was studied by molecular mechanics.28 In the minimized structures of these compounds the 
distances between the 6II-O-yl radical and the extractable hydrogens at H5I are excessively long 
(4.7 and 5.5 Å, respectively) and 1,8-HAT reactions should be clearly unfavorable (see Figure S2 
and Table S4 in the SI for more details). Notwithstanding, the alternative 1,6-HAT of the H1I 
appears possible in the case of compound 32 (dO6II±H1I = 2.7 Å) that would explain the formation 
of spiro ortho ester 30 in the E-CD series. This 1,6-HAT reaction is very unlikely in the D-CD 
series, since in 38 a calculated distance O6II±H1I of 4.6 Å would prevent the formation of the 
corresponding spiro ortho ester. 




To gain insight into the reaction mechanism and clarify the different behavior of the 6I,II-diols in 
the C±H functionalization with respect to the other positional isomers, we carried out the process 
with the corresponding diol in a more simple and conformationally flexible molecule such as the 
hexamethyl E-maltose derivative 41 obtained in three steps from D-(+)-maltose through the silyl-
ether derivatives 40D and 40E (Scheme 8). In this case, the reaction generated a complex mixture 
from which we were able to isolate the ten-membered lactone 42 together with compound 43 in 
only 20% overall yield. Both compounds were found to be unstable toward chromatographic 
purification. This instability does not prevent complete characterization but is presumably 
responsible for the small yield obtained.  
Scheme 8. HAT for the 6I,II-diol-E-maltose 41 
 
The structure and stereochemistry of the ten-membered lactone 42, where all ring protons are 
directly observable in the 1H NMR spectrum, can be now more conveniently and unambiguously 
studied. The NMR data obtained are in quite good agreement with those previously described for 
the ten-membered lactones 31 and 37, which had been obtained mostly using 1D TOCSY. The 
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presence of NOE interactions between H1I and all the protons positioned on the E-face of the 
decanolide ring (H2I, H4I, H4II, and pro-S H6II) seems to indicate a stereoselective D-attack of the 
nucleophile and an R configuration for the C1I. The relative position of the involved ring protons 
and the 3JH,H coupling constants has been checked on a minimized structure where the ten-
membered lactone adopts a boat-chair-chair (BCC) conformation with an (R)-configuration for the 
C1I.36 
While the decanolide formation could be explained by the mechanism shown above, the new 
disaccharide 43 could arise from initial 1,6-hydrogen abstraction by the 6I-O-yl radical from the 
proximal methoxyl group at C4I followed by oxidation and cyclization to form a 1,3-dioxane ring.37 
Then, a second 1,8-abstraction now by the 6II-O-yl radical generates a C5I-radical which finally 
collapses to the oxacarbenium ion and the incorporation of acetate with inversion of configuration. 
Also in this case, the coupling constants for the vicinal ring protons account for a preferred 1C4 
chair conformation for the L-idose unit. The occurrence of this compound sheds some light on the 
mechanism, the less hindered environment permitting this second 1,8-abstraction which in neither 
case was observed when the more restricted 6I,II-diols of E- and D-CDs were used, namely 
compounds 29 (Scheme 5) and 36 (Scheme 7). 
Until now, only mono- and di-alcohols have been investigated. We thought that this study would 
not be complete without trying the reaction with per-6-ol models derived from E- and D-CDs, 2I-
VII
,3I-VII-tetradeca-O-methyl-E-cyclomaltoheptaose38,5f and 2I-VI,3I-VI-dodeca-O-methyl-D-
cyclomaltohexaose,39,5f to find out if we can access to polyfunctionalized compounds through 
multiple radical abstractions. In both substrates, several different conditions were screened in 
which the reagents stoichiometry, temperature, and time were varied, to no avail, only intractable 
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mixtures of products being observed in all instances. Such a result is not very surprising if we 
consider the many possibilities of abstraction and the presumed instability of the products formed.  
CONCLUSIONS 
In summary, we have successfully applied for the first time the remote C±H functionalization logic 
to CD systems. The process is initiated by the 6I-O-yl radical which abstracts with complete 
regioselectivity the hydrogen atom at C5II located in the adjacent D-glucose by a favored 
geometrically restricted nine-membered transition state. Using this methodology with 
monoalcohols derived from D-, E-, and J-CDs two types of structurally modified CDs can be 
obtained in moderate to good yields: a) a new stable 1,3,5-trioxocane ring is formed between the 
two glucopyranose units involved and b) one of the 4C1 glucopyranose residues has been 
transformed into a 1C4 E-L-idose unit by inversion of configuration at C5II. Interestingly, in the case 
of D-CD derivative 7, the conformation of the E-L-idose ring is solvent-dependent, and the 1C4 
conformer is favored in CDCl3 while the equilibrium is strongly shifted toward the 4C1 chair in 
C6D6 solution. This phenomenon that can be readily detected at 26 oC by 1D TOCSY experiments 
is not observable in E- and J-CD analogs 3, 4, and 10.40 
This methodology was also applied to 6I,II-, 6I,III-, and 6I,IV-diols of D- and E-CDs with the intention 
of assessing the viability of two hydrogen abstractions in a simultaneous or tandem fashion, a 
hitherto unknown process.27 
The 6I,IV-diol-E-CD derivative 11 behaved as if the two primary alcohols were independent, the 
expected products with two trioxocane rings 12 and two inverted E-L-idose units 13 being formed 
in good overall yield (Scheme 2). In the reaction of 6I,IV-diol-D-CD derivative 14 a bis(trioxocane) 
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15 was also formed. However, in this more restricted hexameric ring, the corresponding products 
with one or two E-L-idose units were not detected. 
Among the products that can be generated by a double 1,8-abstraction in the reaction of 6I,III-diol-
E-CD 17, three (19, 20 and 21) out of four possible have been obtained (Scheme 3). The only one 
that could not be isolated was the corresponding bis(trioxocane). Instead, the trioxocane±spiro 
ortho ester 22, formed also by a double abstraction, this time 1,8- followed by 1,6-HAT, was 
obtained. Unexpectedly, any attempt to cyclize the plausible intermediates 19-21 by acid catalysis 
failed to produce the bis(trioxocane). A mixture of chromatographically more polar unstable 
compounds presumably containing CD ring fragmentation products was obtained in all cases. 
In sharp contrast to the situation encountered above with 6I,III-diol-E-CD 17, the reaction of 6I,III-
diol-D-CD 23 led to the bis(trioxocane) 24 as the major product. (Scheme 4). Apart from the acid 
instability of the intermediates, we have no satisfactory explanation at the moment to account for 
the fact that the 1,3-bis(trioxocane) is easily formed in the D-CD and not in the E-CD reaction.  
In the case of the 6I,II-diol- of E- and D-CD, 29 and 36 respectively, the proximity of the two alkoxyl 
radicals in adjacent sugar units, facilitates the possibility of interaction between them. This 
situation which has not been presented in the previous diols is responsible for the formation of the 
ten-membered lactones (31 and 37) and the G-lactones (35 and 39). These compounds are obtained 
by the proposed mechanism (vide supra) where the two alkoxyl radicals are involved in the 
formation of the lactonic rings (Schemes 5, 6, and 7).  
To the best of our knowledge, this is the first time that a radical protocol is applied to create 
structural differentiation on the primary face of CDs. Moreover, the mild reaction conditions and 
the good efficiency are remarkable features that make this process a powerful tool to access 
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modified CDs and obtain macrocyclic rings with a different range of functionalization, otherwise 
difficult to achieve, and with potential synthetic and pharmaceutical applications. 
EXPERIMENTAL SECTION 
General Experimental Methods. Melting points were measured on a hot-stage apparatus. Optical 
rotations were recorded on a polarimeter at a wavelength of 589 nm at room temperature in CHCl3 
solutions. IR spectra were recorded on a FT-IR spectrophotometer in film. 1H NMR spectra were 
determined at 500 MHz in CDCl3 or C6D6. Chemical shifts are reported in parts per million (ppm) 
and are calibrated to residual solvent peaks (CHCl3 7.26 ppm and C6H6 7.15 ppm). 13C NMR 
spectra were determined at 125.7 MHz in CDCl3 or C6D6. Chemical shifts are reported in parts per 
million (ppm) and are calibrated to residual solvent peaks (CHCl3 77.0 ppm and C6H6 128.0 ppm). 
NMR peaks assignments and stereochemistries have been established using COSY, TOCSY, 
DEPT, HMBC, HSQC, and ROESY experiments. Low and high resolution mass spectra were 
recorded with a TOF analyzer spectrometer by using electrospray (ESI+). Flash column 
chromatography was performed on Merck silica gel 60 PF (0.063±0.2 mm). Sensitive compounds 
were purified by medium-pressure column chromatography using TLC silica gel 60 F254, scraped 
from Merck Millipore aluminum sheets (Product No. 1055540001), as adsorbent. Reaction 
progress was monitored by thin-layer chromatography (TLC) carried out on 0.25 mm coated 
commercial silica gel plates impregnated with a fluorescent indicator (254 nm). The spray reagents 
for TLC analysis were conducted with 0.5% vanillin in H2SO4±EtOH (4:1) and further heating until 
development of color. Commercially available reagents and solvents were analytical grade or were 
purified by standard procedures prior to use. 
Oxidative HAT of 2I-VII,3I-VII,6II-VII-icosa-O-methyl-E-cyclomaltoheptaose (1) with DIB and 
iodine. Method A: A solution of alcohol 117b (50 mg, 0.035 mmol) in dry CH2Cl2 (2.4 mL) 
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containing DIB (33.4 mg, 0.105 mmol) and I2 (15.5 mg, 0.06 mmol) was stirred under nitrogen at 
30 oC for 0.75 h while irradiated with two 80 W tungsten-filament lamps. An excess of solid 
Na2S2O3 was then added and stirring continued until complete disappearance of the iodine color. 
The reaction mixture was then filtered and concentrated under reduced pressure. Silica gel [Merck 
60 PF (0.063±0.2 mm)] column chromatography of the reaction residue (hexanes±acetone, 65:35) 
afforded cyclo-5VII,6I-anhydro-(5VIIR)-(2,3,6-tri-O-methyl-D-D-xylo-hexos-5-ulopyranosyl)-
ĺ-2,3-di-O-methyl-D-D-glucopyranosyl->ĺ-2,3,6-tri-O-methyl-D-D-glucopyranosyl]5 
(2) (30 mg, 0.021 mmol, 60%): colorless oil, [D]D +138.5 (c 1.78, CHCl3); IR (film): 2929, 1143, 
1107, 1042 cm±1; 1H NMR (500 MHz, CDCl3): G 3.365 (s, 3H), 3.371 (s, 9H), 3.376 (s, 3H), 3.384 
(s, 3H), 3.461 (s, 3H), 3.465 (s, 3H), 3.48 (s, 3H), 3.49 (s, 3H), 3.50 (s, 6H), 3.51 (s, 3H), 3.58 (s, 
3H), 3.60 (s, 3H), 3.62 (s, 6H), 3.63 (s, 3H), 3.64 (s, 3H), 3.69 (s, 3H), 5.06 (d, J = 3.5 Hz, 1H), 
5.06 (d, J = 3.5 Hz, 1H), 5.07 (d, J = 3.8 Hz, 1H), 5.08 (d, J = 3.2 Hz, 1H), 5.14 (d, J = 3.5 Hz, 
1H), 5.20 (d, J = 4.4 Hz, 1H), 5.21 (d, J = 3.8 Hz, 1H); 13C NMR (125.7 MHz, CDCl3): G 57.78 
(CH3), 57.95 (CH3), 58.04 (CH3), 58.36 (CH3), 58.51 (CH3), 58.58 (CH3), 58.86 (3 × CH3), 59.01 
(CH3), 59.03 (3 × CH3), 60.91 (CH3), 61.04 (CH3), 61.26 (CH3), 61.37 (CH3), 61.65 (2 × CH3), 
62.17 (CH3), 64.81 (CH2), 66.88 (CH), 70.74 (CH), 70.78 (CH), 70.90 (CH), 70.92 (CH2), 70.96 
(CH), 70.98 (CH), 70.98 (CH2), 71.23 (CH2), 71.47 (CH2), 71.76 (CH2), 71.94 (CH2), 77.62 (CH), 
79.18 (CH), 79.20 (CH), 79.21 (CH), 80.07 (CH), 80.16 (CH), 80.20 (CH), 80.78 (CH), 81.18 
(CH), 81.20 (CH), 81.46 (CH), 81.51 (CH), 81.57 (CH), 81.70 (CH), 81.81 (2 × CH), 82.06 (2 × 
CH), 82.21 (CH), 82.30 (CH), 82.96 (CH), 96.97 (CH), 97.98 (CH), 98.24 (CH), 99.02 (CH), 99.06 
(CH), 99.15 (CH), 99.39 (CH), 101.04 (C); MS (ESI+-TOF): m/z (%) 1435 [(M + Na)+, 100]; 
HRMS (ESI+-TOF): m/z [M + Na]+ calcd for C62H108NaO35 1435.6569; found 1435.6605. Anal. 
calcd for C62H108O35: C, 52.68; H, 7.70. Found: C, 52.31; H, 7.57. 
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Method B: A solution of alcohol 1 (100 mg, 0.071 mmol) in dry CH2Cl2 (2.9 mL) containing 
DIB (50.3 mg, 0.156 mmol) and I2 (18 mg, 0.071 mmol) was stirred under nitrogen at 30 oC for 
0.5 h while irradiated with two 80 W tungsten-filament lamps. The reaction mixture was then 
poured into 10% aqueous Na2S2O3, extracted with CH2Cl2, dried over Na2SO4, and concentrated. 
The residue was purified by silica gel [Merck 60 PF (0.063±0.2 mm)] column chromatography 
(hexanes±acetone, 65:35) to give 2 (36.3 mg, 0.026 mmol, 36%) and cyclo-(5R)-5VII-O-acetyl-
2,3,6-tri-O-methyl-D-D-xylo-hexos-5-ulopyranosyl-ĺ-2,3-di-O-methyl-D-D-glucopyranosyl-
>ĺ-2,3,6-tri-O-methyl-D-D-glucopyranosyl]5 (3) (62.9 mg, 0.043 mmol, 61%). Compound 3: 
colorless oil, [D]D = +134.5 (c 1.32, CHCl3); IR (film): 3524, 2929, 1734, 1109, 1041 cm±1; 1H 
NMR (500 MHz, CDCl3): G 2.06 (s, 3H), 3.14 (dd, J = 10.1, 3.5 Hz, 1H), 3.15 (dd, J = 10.1, 3.8 
Hz, 1H), 3.18 (dd, J = 9.5, 3.2 Hz, 1H), 3.19 (dd, J = 10.1, 3.5 Hz, 1H), 3.20 (dd, J = 10.1, 3.5 Hz, 
1H), 3.22 (dd, J = 10.1, 3.5 Hz, 1H), 3.31 (dd, J = 9.8, 9.8 Hz, 1H), 3.367 (s, 6H), 3.373 (s, 3H), 
3.38 (s, 3H), 3.39 (s, 3H), 3.40 (s, 3H), 3.42 (s, 3H), 3.45 (s, 3H), 3.475 (s, 3H), 3.478 (s, 3H), 3.49 
(s, 3H), 3.51 (s, 3H), 3.53 (s, 3H), 3.58 (s, 3H), 3.61 (s, 3H), 3.62 (s, 6H), 3.637 (s, 6H), 3.644 (s, 
3H), 3.96 (d, J = 10.1 Hz, 1H, H6aVII), 3.99 (d, J = 9.8 Hz, 1H, H6bVII), 4.04 (br d, J = 1.9 Hz, 1H, 
H4VII), 4.20 (dd, J = 2.5, 2.5 Hz, 1H, H3VII), 4.31 (br d, J = 11.7 Hz, 1H), 5.01 (d, J = 3.2 Hz, 1H), 
5.04 (d, J = 3.2 Hz, 1H), 5.060 (d, J = 2.8 Hz, 1H), 5.061 (d, J = 4.1 Hz, 1H), 5.12 (d, J = 3.8 Hz, 
1H), 5.14 (d, J = 1.9 Hz, 1H, H1VII), 5.18 (d, J = 3.5 Hz, 1H); 1H NMR (500 MHz, CDCl3, 1D-
TOCSY, irradiation at H3VII, 4.20 ppm): G 3.41 (br s, 1H, H2VII), 4.04 (br d, J = 1.9 Hz, 1H, H4VII), 
5.14 (d, J = 1.9 Hz, 1H, H1VII); 1H NMR (500 MHz, C6D6): G 1.72 (s, 3H), 3.10 (dd, J = 9.1, 3.2 
Hz, 1H), 3.13 (dd, J = 9.8, 3.5 Hz, 1H), 3.19 (s, 3H), 3.20 (s, 3H), 3.26 (s, 3H), 3.27 (s, 3H), 3.28 
(s, 3H), 3.30 (s, 6H), 3.31 (s, 3H), 3.32 (s, 3H), 3.39 (s, 3H), 3.40 (s, 6H), 3.41 (s, 3H), 3.46 (s, 
3H), 3.60 (s, 3H), 3.68 (s, 3H), 3.74 (s, 3H), 3.75 (s, 3H), 3.76 (s, 3H), 3.80 (s, 3H), 5.07 (d, J = 
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3.2 Hz, 1H), 5.10 (d, J = 2.8 Hz, 1H), 5.20 (d, J = 3.2 Hz, 1H), 5.27 (d, J = 3.8 Hz, 1H), 5.32 (d, J 
= 3.5 Hz, 1H), 5.45 (d, J = 3.8 Hz, 1H), 5.52 (d, J = 1.6 Hz, 1H, H1II); 13C NMR (125.7 MHz, 
CDCl3): G 22.08 (CH3), 57.27 (CH3), 57.45 (CH3), 58.04 (CH3), 58.37 (CH3), 58.65 (CH3), 58.68 
(CH3), 58.72 (CH3), 58.86 (2 × CH3), 58.93 (CH3), 58.96 (3 × CH3), 59.17 (CH3), 60.16 (CH2), 
61.18 (CH3), 61.25 (CH3), 61.34 (CH3), 61.45 (CH3), 61.52 (CH3), 61.67 (CH3), 70.33 (CH2, 
C6VII), 70.60 (CH), 70.80 (CH2), 70.91 (CH), 70.91 (CH2), 71.01 (CH, C4VII), 71.13 (2 × CH), 
71.13 (2 × CH2), 71.31 (CH2), 71.35 (CH), 71.47 (CH), 75.22 (CH, C3VII), 76.64 (CH, C2VII), 79.43 
(CH), 79.93 (CH), 80.61 (CH), 81.20 (CH), 81.31 (CH), 81.47 (CH), 81.59 (CH), 81.74 (2 × CH), 
81.75 (CH), 81.97 (CH), 82.00 (CH), 82.08 (CH), 82.22 (CH), 82.26 (CH), 82.28 (CH), 82.30 
(CH), 83.15 (CH), 97.59 (CH, C1VII), 99.25 (3 × CH), 99.52 (CH), 99.87 (CH), 100.34 (CH), 
105.03 (C, C5VII), 170.19 (C); MS (ESI+-TOF): m/z (%) 1495 [(M + Na)+, 100]; HRMS (ESI+-
TOF): m/z [M + Na]+ calcd for C64H112NaO37 1495.6780; found 1495.6727. Anal. calcd for 
C64H112O37: C, 52.17; H, 7.66. Found: C, 52.29; H, 7.58. 
Oxidative HAT of 2I-VII,3I-VII,6II-VII-icosa-O-methyl-E-cyclomaltoheptaose (1) with bis(4-tert-
butylbenzoyloxy)iodobenzene and iodine. A solution of alcohol 1 (30 mg, 0.021 mmol) in dry 
CH2Cl2 (0.85 mL) containing bis(4-tert-butylbenzoyloxy)iodobenzene (25.8 mg, 0.046 mmol) and 
I2 (5.3 mg, 0.021 mmol) was stirred under nitrogen at 25 oC for 1.5 h while irradiated with two 80 
W tungsten-filament lamps. The reaction mixture was then directly loaded onto a silica gel (TLC 
Silica gel 60 F254, scraped from Merck Aluminum sheets) column chromatography (hexanes±
DFHWRQHĺWRJLYH2 (13.7 mg, 0.01 mmol, 46%). 
Oxidative HAT of 2I-VII,3I-VII,6II-VII-icosa-O-methyl-E-cyclomaltoheptaose (1) with bis(2,4,6-
trimethylbenzoyloxy)iodobenzene and iodine. A solution of alcohol 1 (90 mg, 0.064 mmol) in dry 
CH2Cl2 (2.6 mL) containing bis(2,4,6-trimethylbenzoyloxy)iodobenzene (101 mg, 0.191 mmol) 
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and I2 (16.2 mg, 0.064 mmol) was stirred under nitrogen at 28 oC for 2 h while irradiated with two 
80 W tungsten-filament lamps. The reaction mixture was then directly loaded onto a silica gel (TLC 
Silica gel 60 F254, scraped from Merck Aluminum sheets) column chromatography (hexanes±
acetone, 70:30) to give 2 (19.3 mg, 0.014 mmol, 21%) and cyclo-(5R)-5VII-O-(2,4,6-
trimethylbenzoyl)-2,3,6-tri-O-methyl-D-D-xylo-hexos-5-ulopyranosyl-ĺ-2,3-di-O-methyl-D-
D-glucopyranosyl->ĺ-2,3,6-tri-O-methyl-D-D-glucopyranosyl]5 (4) (33.1 mg, 0.021 mmol, 
33%). Compound 4: amorphous solid, [D]D +132.5 (c 1.10, CHCl3); IR (film): 2928, 1727, 1455, 
1368, 1192, 1107, 1043 cm±1; 1H NMR (500 MHz, CDCl3): G 2.26 (s, 3H), 2.36 (s, 6H), 3.14 (dd, 
J = 6.9, 3.2 Hz, 1H), 3.17 (m, 5H), 3.21 (dd, J = 5.7, 3.8 Hz, 1H), 3.32 (s, 3H), 3.37 (s, 3H), 3.38 
(s, 3H), 3.39 (s, 3H), 3.40 (s, 3H), 3.40 (s, 3H), 3.41 (s, 3H), 3.44 (s, 3H), 3.48 (s, 3H), 3.48 (s, 
3H), 3.49 (s, 3H), 3.51 (s, 6H), 3.58 (s, 3H), 3.62 (s, 6H), 3.64 (s, 3H), 3.65 (s, 3H), 3.66 (s, 3H), 
4.36 (br d, J = 12.0 Hz), 5.04 (d, J = 2.8 Hz, 1H), 5.07 (m, 3H), 5.13 (d, J = 3.8 Hz, 1H), 5.18 (d, 
J = 3.8 Hz, 1H), 5.36 (d, J = 1.9 Hz, 1H), 6.81 (s, 2H); 1H NMR (500 MHz, C6D6): G 2.03 (s, 3H), 
2.57 (s, 6H), 3.12 (s, 3H), 3.14 (s, 3H), 3.20 (s, 3H), 3.28 (s, 3H), 3.29 (s, 3H), 3.29 (s, 3H), 3.30 
(s, 3H), 3.31 (s, 3H), 3.32 (s, 3H), 3.40 (s, 3H), 3.41 (s, 3H), 3.42 (s, 3H), 3.42 (s, 3H), 3.44 (s, 
3H), 3.60 (s, 3H), 3.68 (s, 3H), 3.73 (s, 3H), 3.75 (s, 3H), 3.77 (s, 3H), 3.79 (s, 3H), 4.67 (d, J = 
9.5 Hz, 1H), 5.09 (d, J = 3.2 Hz, 1H), 5.17 (d, J = 2.8 Hz, 1H), 5.21 (d, J = 3.5 Hz, 1H), 5.26 (d, J 
= 3.8 Hz, 1H), 5.33 (d, J = 3.5 Hz, 1H), 5.47 (d, J = 3.8 Hz, 1H), 5.74 (d, J = 1.9 Hz, 1H), 6.67 (s, 
2H); 13C NMR (125.7 MHz, CDCl3): G 19.53 (2 × CH3), 21.08 (CH3), 57.12 (CH3), 57.27 (CH3), 
58.07 (CH3), 58.37 (CH3), 58.44 (CH3), 58.68 (CH3), 58.70 (CH3), 58.74 (CH3), 58.88 (2 × CH3), 
58.95 (CH3), 58.98 (CH3), 58.99 (CH3), 59.19 (CH3), 60.51 (CH2), 61.00 (CH3), 61.28 (CH3), 61.36 
(CH3), 61.50 (CH3), 61.56 (CH3), 61.72 (CH3), 69.93 (CH2), 70.62 (CH), 70.87 (CH2), 70.91 (CH2), 
70.91 (CH), 71.04 (CH), 71.11 (CH), 71.16 (CH2), 71.20 (CH2), 71.40 (CH), 71.40 (CH2), 71.51 
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(CH), 71.83 (CH), 75.16 (CH), 76.44 (CH), 78.98 (CH), 80.10 (CH), 80.63 (CH), 81.31 (CH), 
81.39 (CH), 81.52 (CH), 81.63 (CH), 81.78 (2 × CH), 81.84 (CH), 81.94 (CH), 81.954 (CH), 82.13 
(CH), 82.26 (CH), 82.31 (CH), 82.36 (2 × CH), 83.19 (CH), 97.40 (CH), 99.13 (CH), 99.26 (CH), 
99.40 (CH), 99.57 (CH), 99.88 (CH), 100.26 (CH), 106.38 (C), 128.37 (2 × CH), 131.24 (C), 
135.26 (2 × C), 139.10 (C), 169.51 (C); MS (ESI+-TOF): m/z (%) 1599 [(M + Na)+, 100]; HRMS 
(ESI+-TOF): m/z [M + Na]+ calcd for C72H120NaO37 1599.7406; found: 1599.7413. Anal. calcd for 
C72H120O37: C, 54.81; H, 7.67. Found: C, 54.60; H, 7.66. 
Oxidative HAT of 2I-VI,3I-VI,6II-VI-heptadeca-O-methyl-D-cyclomaltohexaose (5). Method A: A 
solution of alcohol 525 (30 mg, 0.025 mmol) in dry CH2Cl2 (1 mL) containing DIB (17.6 mg, 0.055 
mmol) and I2 (6.3 mg, 0.025 mmol) was stirred under nitrogen at 21 oC for 1 h while irradiated 
with two 80 W tungsten-filament lamps. An excess of solid Na2S2O3 was then added and stirring 
continued until complete disappearance of the iodine color. The reaction mixture was then filtered and 
concentrated under reduced pressure. Silica gel [Merck 60 PF (0.063±0.2 mm)] column 
chromatography of the reaction residue (hexanes±acetone, 65:35) afforded cyclo-5VI,6I-anhydro-
(5VIR)-(2,3,6-tri-O-methyl-D-D-xylo-hexos-5-ulopyranosyl)-ĺ-2,3-di-O-methyl-D-D-
glucopyranosyl-[(1ĺ4)-2,3,6-tri-O-methyl-D-D-glucopyranosyl]4 (6) (17.7 mg, 0.015 mmol, 59%) 
as a colorless oil: [D]D +127.6 (c 1.24, CHCl3); IR (film): 3052, 2929, 2832 1454, 1365, 1196, 1107 
cm±1; 1H NMR (500 MHz, CDCl3): G 3.12 (dd, J = 10.1, 3.2 Hz, 1H), 3.14 (dd, J = 9.9, 3.3 Hz, 
1H), 3.15 (dd, J = 9.3, 3.6 Hz, 1H), 3.18 (dd, J = 9.8, 3.8 Hz, 1H), 3.19 (dd, J = 9.8, 3.5 Hz, 1H), 
3.25 (dd, J = 9.8, 3.2 Hz, 1H), 3.357 (s, 3H), 3.360 (s, 3H), 3.37 (s, 3H), 3.378 (s, 3H), 3.379 (s, 
3H), 3.469 (s, 3H), 3.470 (s, 3H), 3.483 (s, 3H), 3.488 (s, 3H), 3.493 (s, 3H), 3.51 (s, 3H), 3.58 (s, 
3H), 3.60 (s, 3H), 3.627 (s, 3H), 3.632 (s, 3H), 3.70 (s, 3H), 3.73 (s, 3H), 4.98 (d, J = 3.8 Hz, 1H), 
5.00 (d, J = 3.5 Hz, 1H), 5.03 (d, J = 3.8 Hz, 1H), 5.04 (d, J = 3.5 Hz, 1H), 5.06 (d, J = 3.2 Hz, 
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1H), 5.19 (d, J = 3.5 Hz, 1H); 13C NMR (125.7 MHz, CDCl3): G 57.65 (CH3), 57.80 (2 × CH3), 
57.96 (CH3), 58.31 (CH3), 58.34 (CH3), 58.67 (CH3), 58.72 (CH3), 58.96 (CH3), 59.00 (CH3), 59.07 
(CH3), 61.26 (CH3), 61.45 (CH3), 61.51 (CH3), 61.89 (CH3), 61.98 (CH3), 62.22 (CH3), 63.83 
(CH2), 66.20 (CH), 70.87 (CH), 70.92 (2 × CH), 71.03 (CH2), 71.22 (CH2), 71.55 (CH2), 71.55 
(CH), 71.88 (CH2), 71.97 (CH2), 78.28 (CH), 80.19 (CH), 80.59 (CH), 80.72 (CH), 80.84 (CH), 
81.04 (CH), 81.06 (CH), 81.25 (CH), 81.41 (CH), 81.51 (CH), 81.72 (CH), 82.00 (CH), 82.07 
(CH), 82.10 (CH), 82.29 (CH), 82.31 (CH), 82.59 (CH), 82.67 (CH), 97.35 (CH), 97.59 (CH), 
98.85 (CH), 99.55 (CH), 99.94 (CH), 100.08 (CH), 100.79 (C); 1H NMR (500 MHz, C6D6): G 3.15 
(dd, J = 9.8, 3.5 Hz, 1H), 3.16 (dd, J = 9.1, 4.4 Hz, 1H), 3.19 (dd, J = 9.8, 3.8 Hz, 1H), 3.20 (dd, J 
= 9.9, 3.3 Hz, 1H), 3.24 (dd, J = 9.8, 3.2 Hz, 1H), 3.25 (s, 3H), 3.268 (s, 3H), 3.273 (s, 3H), 3.28 
(s, 3H), 3.30 (s, 3H), 3.31 (s, 3H), 3.317 (s, 3H), 3.320 (s, 3H), 3.34 (s, 3H), 3.46 (s, 3H), 3.50 (s, 
3H), 3.55 (dd, J = 8.8, 7.9 Hz, 1H), 3.67 (s, 3H), 3.68 (s, 3H), 3.70 (s, 3H), 3.80 (s, 3H), 3.82 (s, 
3H), 3.83 (s, 3H), 4.16 (dd, J = 9.5, 9.5 Hz, 1H), 4.27 (d, J = 9.1 Hz, 1H), 4.37 (d, J = 10.1 Hz, 
1H), 4.55 (ddd, J = 10.1, 5.0, 1.3 Hz, 1H), 5.02 (d, J = 3.8 Hz, 1H), 5.17 (d, J = 3.3 Hz, 1H), 5.18 
(d, J = 3.5 Hz, 1H), 5.19 (d, J = 3.2 Hz, 1H), 5.22 (d, J = 3.5 Hz, 1H), 5.24 (d, J = 3.5 Hz, 1H); 13C 
NMR (125.7 MHz, C6D6): G 57.22 (CH3), 57.70 (CH3), 57.84 (CH3), 57.93 (CH3), 58.15 (CH3), 
58.17 (CH3), 58.61 (CH3), 58.72 (CH3), 58.91 (CH3), 59.00 (CH3), 59.03 (CH3), 61.31 (CH3), 61.53 
(CH3), 61.58 (CH3), 61.79 (CH3), 62.08 (CH3), 62.15 (CH3), 64.19 (CH2), 66.85 (CH), 71.42 (CH), 
71.64 (CH), 71.67 (CH2), 71.83 (CH), 72.52 (CH), 72.87 (CH2), 72.92 (2 × CH2), 73.10 (CH2), 
79.14 (CH), 81.49 (CH), 81.60 (2 × CH), 81.69 (CH), 81.76 (CH), 81.89 (CH), 82.03 (CH), 82.09 
(CH), 82.35 (CH), 82.67 (CH), 82.92 (CH), 82.94 (2 × CH), 82.97 (CH), 83.34 (CH), 83.37 (CH), 
83.48 (CH), 98.07 (CH), 98.58 (CH), 99.11 (CH), 99.17 (CH), 99.95 (CH), 100.42 (CH), 101.31 
(C); MS (ESI+-TOF): m/z (%) 1231 [(M + Na)+, 100]; HRMS (ESI+-TOF): m/z [M + Na]+ calcd 
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for C53H92NaO30 1231.5571; found 1231.5543. Anal. calcd for C53H92O30: C, 52.64; H, 7.67. 
Found: C, 52.46; H, 7.76. 
Method B: A solution of alcohol 5 (45 mg, 0.037 mmol) in dry CH2Cl2 (1.5 mL) containing DIB 
(26.2 mg, 0.081 mmol) and I2 (4.7 mg, 0.019 mmol) was stirred under nitrogen at 22 
oC for 1.5 h 
while irradiated with two 80 W tungsten-filament lamps. The reaction mixture was then directly 
loaded onto a silica gel (TLC Silica gel 60 F254, scraped from Merck Aluminum sheets) column 
chromatography (hexanes±acetone, 65:35) to give 6 (14 mg, 0.012 mmol, 31%) and cyclo-(5R)-5VI-
O-acetyl-2,3,6-tri-O-methyl-D-D-xylo-hexos-5-ulopyranosyl-ĺ-2,3-di-O-methyl-D-D-
glucopyranosyl->ĺ-2,3,6-tri-O-methyl-D-D-glucopyranosyl]4 (7) (13.9 mg, 0.011 mmol, 30%). 
Compound 7: colorless oil, [D]D +127.8 (c 0.90, CHCl3); IR (film): 3509, 2933, 1758, 1107, 1041 
cm±1; 1H NMR (500 MHz, CDCl3): G 2.05 (s, 3H), 3.15 (dd, J = 10.1, 3.2 Hz, 1H), 3.15 (dd, J = 
10.1, 3.2 Hz, 1H), 3.16 (dd, J = 9.8, 3.5 Hz, 1H), 3.17 (dd, J = 10.1, 3.5 Hz, 1H), 3.21 (dd, J = 9.5, 
3.2 Hz, 1H), 3.36 (s, 3H), 3.368 (s, 3H), 3.373 (s, 6H), 3.38 (s, 3H), 3.43 (s, 3H), 3.456 (s, 3H), 
3.464 (s, 3H), 3.48 (s, 3H), 3.50 (s, 3H), 3.52 (s, 3H), 3.607 (s, 3H), 3.609 (s, 3H), 3.613 (s, 3H), 
3.62 (s, 3H), 3.64 (s, 3H), 3.68 (s, 3H), 3.91 (d, J = 10.4 Hz, 1H), 3.98 (dd, J = 3.0, 3.0 Hz, 1H), 
4.02 (d, J = 10.4 Hz, 1H), 4.21 (d, J = 3.2 Hz, 1H), 4.23 (m, 1H), 4.97 (d, J = 3.5 Hz, 1H), 5.02 (d, 
J = 3.5 Hz, 1H), 5.03 (d, J = 3.8 Hz, 1H), 5.05 (d, J = 3.2 Hz, 1H), 5.06 (d, J = 3.5 Hz, 1H), 5.23 
(d, J = 2.8 Hz, 1H); 1H NMR (500 MHz, CDCl3, 1D-TOCSY, irradiation at H1
VI, 5.23 ppm): G 
3.43 (br s, 1H, H2VI), 3.99 (dd, J = 3.2, 3.2 Hz, 1H, H3VI), 4.21 (d, J = 2.8 Hz, 1H, H4VI); 1H NMR 
(500 MHz, C6D6): G 1.89 (s, 3H), 3.12 (dd, J = 9.6, 3.3 Hz, 1H), 3.15 (dd, J = 9.8, 3.2 Hz, 1H), 
3.24 (s, 3H), 3.25 (s, 3H), 3.28 (s, 6H), 3.30 (s, 3H), 3.32 (s, 3H), 3.33 (s, 3H), 3.36 (s, 3H), 3.39 
(s, 3H), 3.42 (s, 3H), 3.50 (s, 3H), 3.61 (s, 3H), 3.70 (s, 3H), 3.73 (s, 3H), 3.76 (s, 3H), 3.84 (s, 
3H), 3.87 (s, 3H), 4.74 (d, J = 7.9 Hz, 1H), 5.04 (d, J = 3.2 Hz, 1H), 5.12 (d, J = 3.2 Hz, 1H), 5.19 
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(d, J = 3.5 Hz, 1H), 5.20 (d, J = 3.8 Hz, 1H), 5.22 (d, J = 3.5 Hz, 1H), 5.27 (d, J = 3.5 Hz, 1H); 1H 
NMR (500 MHz, C6D6, 1D-TOCSY, irradiation at H1
VI, 5.27 ppm): G 3.49 (dd, J = 8.5, 2.8 Hz, 
1H, H2VI), 3.73 (dd, J = 7.9, 7.9 Hz, 1H, H3VI), 4.74 (d, J = 7.9 Hz, 1H, H4VI); 13C NMR (125.7 
MHz, CDCl3): G 21.88 (CH3), 57.27 (CH3), 57.74 (CH3), 57.80 (CH3), 58.11 (CH3), 58.33 (CH3), 
58.36 (CH3), 58.71 (CH3), 58.82 (CH3), 58.86 (CH3), 58.93 (CH3), 59.04 (CH3), 59.08 (CH3), 61.21 
(CH2), 61.48 (CH3), 61.62 (CH3), 61.66 (CH3), 61.77 (CH3), 61.92 (CH3), 70.84 (CH), 70.92 (CH2), 
71.14 (CH2), 71.16 (CH), 71.35 (2 × CH2), 71.68 (CH), 71.79 (CH), 71.83 (CH2), 72.17 (CH), 
74.04 (CH), 76.44 (CH), 77.31 (CH), 80.57 (CH), 81.10 (CH), 81.21 (CH), 81.41 (CH), 81.49 
(CH), 81.54 (CH), 81.57 (CH), 81.92 (CH), 82.19 (CH), 82.25 (CH), 82.33 (2 × CH), 82.40 (CH), 
82.57 (CH), 82.65 (CH), 97.26 (CH), 98.28 (CH), 99.78 (CH), 99.89 (CH), 100.41 (CH), 101.39 
(CH), 103.99 (C), 169.76 (C); 13C NMR (125.7 MHz, C6D6): G 22.36 (CH3), 57.35 (CH3), 57.54 
(CH3), 57.81 (CH3), 57.83 (CH3), 58.22 (2 × CH3), 58.80 (CH3), 58.82 (CH3), 58.93 (CH3), 59.01 
(CH3), 59.87 (CH3), 60.41 (CH3), 61.60 (CH3), 61.71 (CH3), 61.75 (CH3), 61.79 (CH3), 61.80 
(CH3), 62.77 (CH2), 71.94 (CH), 72.01 (CH), 72.01 (CH2), 72.17 (2 × CH2), 72.31 (CH), 72.60 
(CH2), 72.60 (CH), 73.22 (CH2), 73.39 (CH), 79.60 (CH), 80.56 (CH), 80.96 (CH), 81.10 (CH), 
81.94 (CH), 81.98 (CH), 82.28 (CH), 82.39 (CH), 82.41 (CH), 82.57 (2 × CH), 82.60 (CH), 82.73 
(CH), 82.94 (CH), 83.09 (CH), 83.16 (CH), 83.26 (2 × CH), 98.68 (CH), 99.22 (CH), 99.58 (CH), 
99.99 (CH), 100.28 (CH), 100.62 (CH), 104.57 (C), 169.11 (C); MS (ESI+-TOF): m/z (%) 1291 
[(M + Na)+, 100]; HRMS (ESI+-TOF): m/z [M + Na]+ calcd for C55H96NaO32 1291.5782; found 
1291.5819. Anal. calcd for C55H96O32: C, 52.04; H, 7.62. Found: C, 52.25; H, 7.49. 
Oxidative HAT of 2I-VIII,3I-VIII,6II-VIII-tricosa-O-methyl-J-cyclomaltooctaose (8). Method A: A 
solution of alcohol 826 (31 mg, 0.019 mmol) in dry CH2Cl2 (0.78 mL) containing DIB (113.5 mg, 
0.042 mmol) and I2 (4.8 mg, 0.019 mmol) was stirred under nitrogen at 25 
oC for 1 h while 
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irradiated with two 80 W tungsten-filament lamps. An excess of solid Na2S2O3 was then added and 
stirring continued until complete disappearance of the iodine color. The reaction mixture was then 
filtered and concentrated under reduced pressure. Silica gel [Merck 60 PF (0.063±0.2 mm)] column 
chromatography of the reaction residue (hexanes±acetone, 60:40) afforded cyclo-5VIII,6I-anhydro-
(5VIIIR)-(2,3,6-tri-O-methyl-D-D-xylo-hexos-5-ulopyranosyl)-ĺ-2,3-di-O-methyl-D-D-
glucopyranosyl->ĺ-2,3,6-tri-O-methyl-D-D-glucopyranosyl]6 (9) (13.6 mg, 0.008 mmol, 44%): 
colorless oil, [D]D +130.9 (c 1.380, CHCl3); IR (film): 2929, 1141, 1104, 1039 cm±1; 1H NMR (500 
MHz, CDCl3): G 3.14±3.29 (m, 8H), 3.34 (s, 3H), 3.36 (s, 3H), 3.37 (s, 3H), 3.377 (s, 3H), 3.379 
(s, 3H), 3.39 (s, 3H), 3.459 (s, 3H), 3.464 (s, 3H), 3.47 (s, 3H), 3.48 (s, 3H), 3.491 (s, 3H), 3.495 
(s, 6H), 3.50 (s, 3H), 3.51 (s, 3H), 3.54 (s, 3H), 3.58 (s, 3H), 3.59 (s, 3H), 3.603 (s, 3H), 3.606 (s, 
3H), 3.611 (s, 3H), 3.639 (s, 3H), 3.643 (s, 3H), 5.08 (d, J = 3.8 Hz, 1H), 5.18 (d, J = 3.2 Hz, 1H), 
5.20 (d, J = 3.8 Hz, 1H), 5.21 (d, J = 3.8 Hz, 1H), 5.22 (d, J = 4.1 Hz, 1H), 5.24 (d, J = 2.2 Hz, 
1H), 5.25 (d, J = 2.8 Hz, 1H), 5.58 (d, J = 3.5 Hz, 1H); 13C NMR (125.7 MHz, CDCl3): G 57.46 
(CH3), 57.74 (CH3), 58.34 (CH3), 58.41 (CH3), 58.48 (CH3), 58.51 (CH3), 58.85 (2 × CH3), 58.88 
(CH3), 58.93 (2 × CH3), 58.96 (CH3), 58.99 (CH3), 59.20 (2 × CH3), 59.60 (CH3), 59.99 (CH3), 
60.37 (CH3), 60.98 (CH3), 61.02 (2 × CH3), 61.20 (CH3), 61.70 (CH3), 64.44 (CH2), 66.25 (CH), 
69.00 (CH), 69.90 (CH), 70.18 (CH), 70.22 (CH2), 70.55 (CH), 70.78 (CH), 70.91 (CH), 71.04 
(CH2), 71.08 (2 × CH2), 71.21 (CH), 71.64 (CH2), 71.94 (CH2), 72.18 (CH2), 74.47 (CH), 77.13 
(CH), 77.62 (CH), 77.92 (CH), 78.05 (CH), 78.58 (CH), 79.62 (CH), 79.72 (CH), 80.67 (CH), 
81.17 (CH), 81.58 (CH), 81.63 (CH), 81.69 (3 × CH), 81.81 (CH), 82.28 (CH), 82.31 (CH), 82.46 
(CH), 82.61 (CH), 82.76 (CH), 83.02 (CH), 83.18 (CH), 92.88 (CH), 95.20 (CH), 96.85 (CH), 
97.59 (CH), 97.84 (CH), 98.35 (CH), 98.82 (CH), 99.55 (CH), 100.64 (C); MS (ESI+-TOF): m/z 
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(%) 1639 [(M + Na)+, 100]; HRMS (ESI+-TOF): m/z [M + Na]+ calcd for C71H124NaO40 1639.7567; 
found 1639.7531. Anal. calcd for C71H124O40: C, 52.71; H, 7.73. Found: C, 52.86; H, 7.55. 
Method B: A solution of alcohol 8 (45 mg, 0.028 mmol) in dry CH2Cl2 (1.2 mL) containing DIB 
(20 mg, 0.062 mmol) and I2 (3.6 mg, 0.014 mmol) was stirred under nitrogen at 24 oC for 2.5 h 
while irradiated with two 80 W tungsten-filament lamps. The reaction mixture was then directly 
loaded onto a silica gel (TLC Silica gel 60 F254, scraped from Merck Aluminum sheets) column 
chromatography (hexanes±acetone, 65:35) to give 9 (15.6 mg, 0.01 mmol, 36%) and cyclo-(5R)-5VIII-
O-acetyl-2,3,6-tri-O-methyl-D-D-xylo-hexos-5-ulopyranosyl-ĺ-2,3-di-O-methyl-D-D-
glucopyranosyl-[(1ĺ4)-2,3,6-tri-O-methyl-D-D-glucopyranosyl]6 (10) (19.2 mg, 0.011 mmol, 
41%). Compound 10: colorless oil, [D]D +131.6 (c 0.91, CHCl3); IR (film): 3539, 2925, 1738, 1152, 
1100, 1037 cm±1; 1H NMR (500 MHz, CDCl3): G 2.06 (s, 3H), 3.16 (dd, J = 9.5, 3.2 Hz, 1H), 3.19 
(dd, J = 9.8, 3.5 Hz, 1H), 3.19 (dd, J = 9.8, 3.5 Hz, 1H), 3.19 (dd, J = 9.8, 3.5 Hz, 1H), 3.21 (dd, J 
= 9.6, 3.6 Hz, 1H), 3.23 (dd, J = 9.5, 3.8 Hz, 1H), 3.26 (dd, J = 9.8, 3.8 Hz, 1H), 3.330 (s, 3H), 
3.334 (s, 3H), 3.34 (s, 3H), 3.36 (s, 3H), 3.369 (s, 3H), 3.374 (s, 3H), 3.40 (s, 3H), 3.42 (s, 3H), 
3.44 (br d, J = 3.9 Hz, 1H, H2VIII), 3.473 (s, 6H), 3.476 (s, 3H), 3.477 (s, 3H), 3.51 (s, 3H), 3.556 
(s, 3H), 3.558 (s, 3H), 3.58 (s, 3H), 3.60 (s, 6H), 3.62 (s, 3H), 3.64 (s, 3H), 3.649 (s, 3H), 3.654 (s, 
3H), 3.71 (s, 3H), 3.99 (d, J = 9.8 Hz, 1H), 4.025 (d, J = 9.8 Hz, 1H), 4.03 (br s, 1H, H4VIII), 4.24 
(dd, J = 2.2, 2.2 Hz, 1H, H3VIII), 5.01 (d, J = 3.5 Hz, 1H), 5.08 (d, J = 3.2 Hz, 1H), 5.09 (d, J = 3.5 
Hz, 1H), 5.12 (d, J = 3.8 Hz, 1H), 5.18 (d, J = 3.8 Hz, 1H), 5.19 (d, J = 3.5 Hz, 1H), 5.23 (d, J = 
1.6 Hz, 1H, H1VIII), 5.60 (d, J = 4.1 Hz, 1H); 1H NMR (500 MHz, CDCl3, 1D-TOCSY, irradiation 
at H1II, 5.23 ppm): G 3.45 (d, J = 3.9 Hz, 1H, H2VIII), 4.03 (br s, 1H, H4VIII), 4.25 (dd, J = 2.4, 2.4 
Hz, 1H, H3VIII); 1H NMR (500 MHz, C6D6): G 1.77 (s, 3H), 3.10 (dd, J = 9.5, 2.8 Hz, 1H), 3.13 
(dd, J = 9.9, 3.3 Hz, 1H), 3.19 (s, 3H), 3.21 (s, 3H), 3.22 (s, 3H), 3.27 (s, 3H), 3.29 (m, 6H), 3.296 
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(s, 3H), 3.304 (s, 3H), 3.31 (s, 3H), 3.322 (s, 3H), 3.325 (s, 3H), 3.35 (s, 3H), 3.36 (s, 3H), 3.37 (s, 
3H), 3.39 (s, 3H), 3.46 (s, 3H), 3.59 (s, 3H), 3.65 (s, 3H), 3.70 (s, 3H), 3.72 (s, 3H), 3.726 (s, 3H), 
3.733 (s, 3H), 3.81 (s, 3H), 4.30 (dd, J = 2.5, 2.5 Hz, 1H), 4.32 (br s), 4.40 (d, J = 9.8 Hz, 1H), 4.46 
(br d, J = 12.0 Hz, 1H), 4.51 (d, J = 9.8 Hz, 1H), 5.16 (d, J = 3.2 Hz, 1H), 5.17 (d, J = 3.2 Hz, 1H), 
5.29 (d, J = 3.5 Hz, 1H), 5.36 (d, J = 3.8 Hz, 1H), 5.37 (d, J = 3.8 Hz, 1H), 5.57 (d, J = 3.8 Hz, 
1H), 5.61 (d, J = 3.8 Hz, 1H), 5.65 (d, J = 1.6 Hz, 1H); 13C NMR (125.7 MHz, CDCl3): G 22.11 
(CH3), 57.40 (CH3), 58.07 (CH3), 58.18 (CH3), 58.38 (CH3), 58.40 (CH3), 58.46 (CH3), 58.60 
(CH3), 58.84 (CH3), 58.88 (CH3), 58.96 (4 × CH3), 59.10 (CH3), 59.64 (2 × CH3), 60.12 (CH3), 
60.22 (CH2), 61.02 (CH3), 61.33 (CH3), 61.39 (CH3), 61.46 (CH3), 61.55 (CH3), 61.70 (CH3), 70.18 
(CH), 70.42 (CH2), 70.60 (CH), 70.71 (CH2), 70.78 (CH), 70.88 (CH2), 70.92 (CH2), 70.99 (CH2), 
71.12 (CH), 71.12 (CH2), 71.21 (2 × CH), 71.58 (CH), 71.68 (CH2), 72.36 (CH), 72.48 (CH), 75.45 
(CH), 76.33 (CH), 78.79 (CH), 78.99 (CH), 79.35 (CH), 80.43 (CH), 80.45 (CH), 81.37 (CH), 
81.57 (3 × CH), 81.74 (2 × CH), 81.97 (CH), 82.04 (CH), 82.07 (CH), 82.33 (2 × CH), 82.38 (CH), 
82.57 (CH), 82.60 (CH), 82.99 (CH), 96.50 (CH), 97.53 (CH), 97.85 (CH), 98.07 (CH), 98.71 
(CH), 99.05 (CH), 100.00 (CH), 101.56 (CH), 105.34 (C), 170.23 (C); MS (ESI+-TOF): m/z (%) 
1699 [(M + Na)+, 100]; HRMS (ESI+-TOF): m/z [M + Na]+ calcd for C73H128NaO42 1699.7778; 
found 1699.7756. Anal. calcd for C73H128O42: C, 52.26; H, 7.69. Found: C, 52.15; H, 7.53. 
2I-VI,3I-VI,6II,III,V,VI-Hexadeca-O-methyl-D-cyclomaltohexaose (14), 2I-VI,3I-VI,6II,IV-VI-Hexadeca-
O-methyl-D-cyclomaltohexaose (23), and 2I-VI,3I-VI,6III-VI-Hexadeca-O-methyl-D-
cyclomaltohexaose (36). A solution of dry D-cyclodextrin (4.69 g, 4.825 mmol) and imidazole 
(1.148 g, 16.9 mmol) in dry DMF (246 mL) was added TBDMSCl (2.654 g, 9.7 mmol) in one 
portion at room temperature under nitrogen and the mixture stirred at this temperature for 2 h. After 
cooling at 0 oC, NaH (60%, 10.615 g, 265 mmol) was added in small portions and the mixture 
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stirred for 30 min and then at room temperature for 1 h. After recooling to 0 oC, MeI (34.2 mL, 549 
mmol) was then added dropwise and the stirring continued at room temperature overnight. The 
excess of NaH was destroyed with MeOH and the mixture poured into ice-water and extracted with 
CHCl3 (5 × 100 mL). The organic phase was dried over Na2SO4 and concentrated under reduced 
pressure. The residue in dry MeOH (290 mL) was treated with NH4F (6.28 g, 170 mmol) and heated 
at reflux temperature under nitrogen for 22.5 h. The solvent was evaporated under reduced pressure 
and the residue redissolved in CHCl3 (200 mL), filtered over Celite and concentrated to give a 
crude mixture (12.15 g) that was purified by column chromatography (CHCl3 ĺ&+&O3±MeOH, 
96:4) to give the known permethylated D-CD (628 mg, 0.513 mmol, 10%), 2I-VI,3I-VI,6II-VI-
heptadeca-O-methyl-D-cyclomaltohexaose (5)25 (1602 mg, 1.324 mmol, 27%), and a mixture of 
the three possible diols that was subjected to a second careful flash chromatography on 60 PF silica 
gel (0.04±0.063) (CHCl3±0H2+ĺWRJLYHWKHGLROV1425,29 (385 mg, 0.322 mmol, 7%), 
23 (731 mg, 0.611 mmol, 13%), and 3635 (936 mg, 0.783 mmol, 16%). A more polar fraction 
containing a mixture of triols and other polyols was not studied. Compound 23: colorless oil, [D]D 
+141.2 (c 0.97, CHCl3); IR (film): 3472, 2929, 1454, 1365, 1107, 1039 cm
±1; 1H NMR (500 MHz, 
CDCl3): G 3.13±3.19 (m, 6H), 3.389 (s, 3H), 3.397 (s, 3H), 3.398 (s, 6H), 3.489 (s, 3H), 3.492 (s, 
3H), 3.495 (s, 6H), 3.50 (s, 6H), 3.63 (s, 3H), 3.647 (s, 6H), 3.649 (s, 3H), 3.650 (s, 3H), 3.66 (s, 
3H), 5.03 (d, J = 3.8 Hz, 1H), 5.035 (d, J = 3.8 Hz, 1H), 5.05 (d, J = 3.5 Hz, 1H), 5.06 (d, J = 3.5 
Hz, 1H), 5.07 (d, J = 3.5 Hz, 1H), 5.08 (d, J = 3.5 Hz, 1H); 13C NMR (125.7 MHz, CDCl3): G 57.85 
(2 × CH3), 57.90 (2 × CH3), 58.03 (CH3), 58.08 (CH3), 58.93 (CH3), 59.01 (CH3), 59.09 (CH3), 
59.15 (CH3), 61.63 (2 × CH3), 61.75 (2 × CH3), 61.77 (CH3), 61.79 (CH3), 62.32 (CH2), 62.40 
(CH2), 71.19 (CH), 71.28 (2 × CH), 71.43 (CH2), 71.51 (CH), 71.53 (CH2), 71.55 (CH2), 71.69 
(CH2), 72.48 (CH), 72.65 (CH), 81.24 (CH), 81.28 (3 × CH), 81.35 (CH), 81.40 (CH), 81.74 (CH), 
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81.97 (CH), 82.00 (CH), 82.06 (2 × CH), 82.12 (CH), 82.17 (2 × CH), 82.22 (2 × CH), 82.29 (CH), 
82.35 (CH), 99.36 (CH), 99.58 (CH), 99.84 (CH), 99.87 (2 × CH), 99.90 (CH); MS (ESI+-TOF): 
m/z (%) 1214 [(M + NH4)
+, 100]; HRMS (ESI+-TOF): m/z [M + NH4]
+ calcd for C52H96NO30 
1214.6017; found 1214.6023. Anal. calcd for C52H92O30: C, 52.17; H, 7.75. Found: C, 52.05; H, 
7.61. Compound 36: colorless oil, [D]D +143.3 (c 1.21, CHCl3); IR (film): 3468, 2933, 1456, 1365, 
1109, 1037 cm±1; 1H NMR (500 MHz, CDCl3): G 3.12±3.19 (m, 6H), 3.386 (s, 6H), 3.390 (s, 6H), 
3.477 (s, 3H), 3.485 (s, 6H), 3.492 (s, 3H), 3.497 (s, 3H), 3.501 (s, 3H), 3.632 (s, 3H), 3.637 (s, 
3H), 3.640 (s, 3H), 3.642 (s, 3H), 3.644 (s, 3H), 3.65 (s, 3H), 5.01 (d, J = 3.5 Hz, 1H), 5.04 (d, J = 
3.2 Hz, 4H), 5.08 (d, J = 3.5 Hz, 1H); 13C NMR (125.7 MHz, CDCl3): G 57.85 (CH3), 57.90 (3 × 
CH3), 57.97 (2 × CH3), 58.94 (2 × CH3), 59.00 (CH3), 59.09 (CH3), 61.67 (CH3), 61.72 (3 × CH3), 
61.77 (2 × CH3), 62.20 (CH2), 62.54 (CH2), 71.14 (CH), 71.17 (CH), 71.25 (2 × CH), 71.44 (CH2), 
71.51 (2 × CH2), 71.60 (CH2), 72.59 (CH), 72.98 (CH), 81.26 (2 × CH), 81.30 (4 × CH), 81.99 (3 
× CH), 82.06 (2 × CH), 82.15 (2 × CH), 82.16 (CH), 82.22 (CH), 82.26 (CH), 82.45 (CH), 82.58 
(CH), 99.58 (CH), 99.66 (CH), 99.76 (CH), 99.86 (CH), 99.89 (CH), 99.94 (CH); MS (ESI+-TOF): 
m/z (%) 1219 [(M + Na)+, 100]; HRMS (ESI+-TOF): m/z [M + Na]+ calcd for C52H92NaO30 
1219.5571; found 1219.5576. Anal. calcd for C52H92O30: C, 52.17; H, 7.75. Found: C, 52.30; H, 
7.74. 
Oxidative HAT of 2I-VII,3I-VII,6II,III,V-VII-nonadeca-O-methyl-E-cyclomaltoheptaose (11). A 
solution of alcohol 1117a (80 mg, 0.057 mmol) in dry CH2Cl2 (2.3 mL) containing DIB (55 mg, 
0.171 mmol) and I2 (24.6 mg, 0.097 mmol) was stirred under nitrogen at 30 
oC for 1 h while 
irradiated with two 80 W tungsten-filament lamps. The reaction mixture was then poured into 10% 
aqueous Na2S2O3, extracted with CH2Cl2, dried over Na2SO4, and concentrated. The residue was 
purified by silica gel [Merck 60 PF (0.063±0.2 mm)] column chromatography (hexanes±acetone, 
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glucopyranosyl]2 (12) (16.2 mg, 0.012 mmol, 20%), an inseparable mixture of mono-trioxocane±




methyl-D-D-glucopyranosyl]2 (13) (42.3 mg, 0.028 mmol, 49%). Compound 12: colorless oil, [D]D 
+110.9 (c 0.79, CHCl3); IR (film): 2933, 1454, 1365, 1139, 1065, 1044 cm
±1; 1H NMR (500 MHz, 
CDCl3): G 3.11 (dd, J = 9.8, 3.2 Hz, 1H), 3.13 (dd, J = 9.5, 3.2 Hz, 1H), 3.179 (dd, J = 9.5, 3.5 Hz, 
1H), 3.181 (dd, J = 9.5, 3.5 Hz, 1H), 3.21 (dd, J = 9.8, 3.8 Hz, 1H), 3.28 (dd, J = 9.5, 3.2 Hz, 1H), 
3.28 (dd, J = 9.5, 3.2 Hz, 1H), 3.37 (s, 3H), 3.378 (s, 3H), 3.380 (s, 6H), 3.39 (s, 3H), 3.465 (s, 
3H), 3.468 (s, 3H), 3.47 (s, 3H), 3.478 (s, 3H), 3.484 (s, 3H), 3.50 (s, 3H), 3.52 (s, 3H), 3.59 (s, 
3H), 3.601 (s, 3H), 3.604 (s, 3H), 3.62 (s, 3H), 3.63 (s, 3H), 3.67 (s, 3H), 3.69 (s, 3H), 5.02 (d, J = 
3.5 Hz, 1H), 5.04 (d, J = 2.8 Hz, 1H), 5.053 (d, J = 3.5 Hz, 1H), 5.058 (d, J = 3.8 Hz, 1H), 5.066 
(d, J = 4.1 Hz, 1H), 5.21 (d, J = 3.8 Hz, 1H), 5.22 (d, J = 3.5 Hz, 1H); 13C NMR (125.7 MHz, 
CDCl3): G 57.74 (CH3), 57.94 (2 × CH3), 58.04 (CH3), 58.08 (CH3), 58.33 (CH3), 58.43 (CH3), 
58.95 (4 × CH3), 59.06 (CH3), 61.09 (2 × CH3), 61.66 (CH3), 61.86 (CH3), 61.89 (CH3), 62.18 
(CH3), 62.25 (CH3), 64.71 (CH2, C6
I or C6IV), 65.14 (CH2, C6
I or C6IV), 66.65 (CH, C5I or C5IV), 
67.21 (CH, C5I or C5IV), 70.76 (CH2), 70.85 (CH), 70.87 (CH), 70.92 (CH), 70.98 (CH2), 71.10 
(CH2), 71.74 (CH2), 72.05 (CH2), 77.64 (CH, C4
I or C4IV), 77.79 (CH, C4I or C4IV), 78.00 (CH), 
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79.14 (CH), 79.28 (CH), 79.95 (CH), 80.10 (CH), 80.48 (CH), 80.83 (CH), 80.98 (CH), 81.11 
(CH), 81.35 (CH), 81.50 (CH), 81.63 (2 × CH), 81.74 (CH), 81.94 (2 × CH), 82.78 (CH), 83.26 
(CH), 83.36 (CH), 96.92 (CH), 97.05 (CH), 97.78 (CH), 98.28 (CH), 99.08 (CH), 99.78 (CH, C1I 
or C1IV), 100.59 (CH, C1I or C1IV), 100.77 (C, C5I or C5IV), 101.17 (C, C5I or C5IV); MS (ESI+-
TOF): m/z (%) 1419 [(M + Na)+, 100]; HRMS (ESI+-TOF): m/z [M + Na]+ calcd for C61H104NaO35 
1419.6256; found 1419.6250. Anal. calcd for C61H104O35: C, 52.43; H, 7.50. Found: C, 52.48; H, 
7.34. 
Some spectroscopic data of the inseparable mixture of mono-trioxocane±mono-acetyl positional 
isomers could be obtained: colorless oil, 1H NMR (500 MHz, CDCl3, complex spectrum, only 
clearly distinguished signals are reported): G 2.062 (s, 3H), 2.064 (s, 3H), 4.15 (dd, J = 2.5, 2.5 Hz, 
1H), 4.17 (dd, J = 2.4, 2.4 Hz, 1H), 4.96 (d, J = 3.5 Hz, 1H), 5.01 (d, J = 3.5 Hz, 1H), 5.041 (d, J 
= 3.5 Hz, 1H), 5.05 (d, J = 4.4 Hz, 2H), 5.06 (d, J = 3.2 Hz, 2H), 5.07 (d, J = 3.2 Hz, 1H), 5.10 (d, 
J = 3.5 Hz, 1H), 5.12 (d, J = 3.5 Hz, 1H), 5.14 (d, J = 2.2 Hz, 1H), 5.17 (d, J = 2.2 Hz, 1H), 5.227 
(d, J = 3.4 Hz, 1H), 5.229 (d, J = 3.5 Hz, 1H); 13C NMR (125.7 MHz, CDCl3, complex spectrum, 
only clearly distinguished signals are reported): G 22.02 (CH3), 22.06 (CH3), 60.31 (CH2), 60.37 
(CH2), 64.84 (CH2), 64.91 (CH2), 66.91 (CH), 67.07 (CH), 96.98 (CH), 97.01 (CH), 97.21 (CH), 
97.33 (CH), 97.46 (CH), 97.89 (CH), 99.12 (CH), 99.24 (CH), 99.62 (CH), 99.83 (CH), 100.17 
(CH), 100.24 (CH), 100.40 (CH), 101.05 (C), 101.45 (C), 101.93 (CH), 104.51 (C), 104.55 (C), 
170.14 (C); MS (ESI+-TOF): m/z (%) 1479 [(M + Na)+, 100]; HRMS (ESI+-TOF): m/z [M + Na]+ 
calcd for C63H108NaO37 1479.6467; found 1479.6475. 
Compound 13: colorless oil, [D]D +130.8 (c 0.75, CHCl3); IR (film): 2933, 1732, 1454, 1367, 
1193, 1106, 1046 cm±1; 1H NMR (500 MHz, CDCl3): G 2.04 (s, 6H), 3.12 (dd, J = 9.3, 2.7 Hz, 1H), 
3.15 (dd, J = 6.9, 3.2 Hz, 1H), 3.16 (dd, J = 7.6, 3.5 Hz, 1H), 3.22 (dd, J = 9.8, 3.2 Hz, 1H), 3.26 
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(dd, J = 9.8, 3.5 Hz, 1H), 3.367 (s, 6H), 3.370 (s, 3H), 3.38 (s, 3H), 3.39 (s, 3H), 3.40 (s, 6H), 3.458 
(s, 3H), 3.461 (s, 3H), 3.463 (s, 3H), 3.49 (s, 3H), 3.50 (s, 3H), 3.52 (s, 3H), 3.588 (s, 3H), 3.591 
(s, 3H), 3.595 (s, 3H), 3.598 (s, 3H), 3.617 (s, 3H), 3.619 (s, 3H), 3.90 (d, J = 9.8 Hz, 1H, H6), 
3.95 (d, J = 9.8 Hz, 1H, H6), 4.00 (d, J = 9.8 Hz, 1H, H6), 4.03 (d, J = 9.8 Hz, 1H, H6), 4.05 (br d, 
J = 2.5 Hz, 1H, H4VII), 4.08 (dd, J = 2.5, 2.5 Hz, 1H, H3III), 4.16 (dd, J = 2.5, 2.5 Hz, 1H, H3VII), 
4.33 (br dd, J = 11.0, 7.3 Hz, 1H), 4.41 (br dd, J = 11.5, 5.8 Hz, 1H), 4.97 (d, J = 2.8 Hz, 1H), 4.98 
(d, J = 3.2 Hz, 1H), 5.03 (d, J = 3.5 Hz, 1H), 5.04 (d, J = 3.2 Hz, 1H), 5.09 (d, J = 3.2 Hz, 1H), 
5.11 (d, J = 1.9 Hz, 1H, H1III), 5.14 (d, J = 1.9 Hz, 1H, H1VII); 1H NMR (500 MHz, CDCl3, 1D-
TOCSY, irradiation at H1VII, 5.14 ppm): G 3.40 (br s, 1H, H2VII), 4.05 (br s, 1H, H4VII), 4.17 (dd, 
J = 2.5, 2.5 Hz, 1H, H3VII); 1H NMR (500 MHz, CDCl3, 1D-TOCSY, irradiation at H1
III, 5.11 
ppm): G 3.32 (br s, 1H, H2III), 4.02 (br s, 1H, H4III), 4.09 (dd, J = 2.5, 2.5 Hz, 1H, H3III); 1H NMR 
(500 MHz, C6D6, 18 
oC): G 1.74 (s, 3H), 1.78 (s, 3H), 3.16 (s, 3H), 3.18 (s, 3H), 3.19 (s, 3H), 3.21 
(s, 3H), 3.26 (s, 3H), 3.270 (s, 3H), 3.274 (s, 6H), 3.30 (s, 9H), 3.40 (s, 3H), 3.61 (s, 3H), 3.62 (s, 
3H), 3.66 (s, 3H), 3.72 (s, 3H), 3.822 (s, 3H), 3.825 (s, 3H), 3.85 (s, 3H), 4.44 (d, J = 9.8 Hz, 1H), 
4.51 (d, J = 9.8 Hz, 1H), 5.08 (d, J = 3.2 Hz, 1H), 5.09 (d, J = 3.5 Hz, 1H), 5.15 (d, J = 2.5 Hz, 
1H), 5.18 (d, J = 3.8 Hz, 1H), 5.19 (d, J = 2.8 Hz, 1H), 5.59 (d, J = 1.3 Hz, 1H), 5.63 (d, J = 1.3 
Hz, 1H); 1H NMR (500 MHz, C6D6, 70 
oC): G 1.79 (s, 3H), 1.83 (s, 3H), 3.21 (s, 3H), 3.23 (s, 3H), 
3.25 (s, 3H), 3.27 (s, 3H), 3.29 (s, 3H), 3.308 (s, 3H), 3.312 (s, 3H), 3.313 (s, 3H), 3.319 (s, 3H), 
3.322 (s, 3H), 3.34 (s, 3H), 3.39 (s, 3H), 3.60 (s, 3H), 3.61 (s, 3H), 3.699 (s, 3H), 3.702 (s, 3H), 
3.79 (s, 3H), 3.80 (s, 3H), 3.83 (s, 3H), 4.10 (dd, J = 11.2, 3.9 Hz, 1H), 4.40 (d, J = 9.8 Hz, 1H), 
4.44 (d, J = 9.8 Hz, 1H), 5.05 (d, J = 3.2 Hz, 1H), 5.07 (d, J = 3.5 Hz, 1H), 5.11 (d, J = 2.5 Hz, 
1H), 5.13 (d, J = 3.5 Hz, 1H), 5.16 (d, J = 2.8 Hz, 1H), 5.56 (d, J = 1.6 Hz, 1H), 5.65 (d, J = 1.3 
Hz, 1H); 13C NMR (125.7 MHz, CDCl3): G 21.98 (CH3), 22.03 (CH3), 57.16 (CH3), 57.41 (CH3), 
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57.68 (CH3), 57.75 (CH3), 57.86 (CH3), 58.84 (CH3), 58.90 (CH3), 58.99 (4 × CH3), 59.03 (CH3), 
59.34 (CH3), 59.68 (CH3), 59.91 (CH2), 60.37 (CH2), 61.02 (CH3), 61.11 (CH3), 61.55 (CH3), 61.72 
(CH3), 61.77 (CH3), 70.44 (CH), 70.48 (CH2), 70.60 (CH2), 70.66 (CH2), 70.86 (CH2), 70.87 (CH2), 
71.08 (CH), 71.30 (2 × CH), 71.59 (CH), 71.67 (CH), 72.16 (CH), 76.11 (CH, C3VII), 76.65 (CH, 
C2VII), 76.86 (CH, C2III), 77.06 (CH, C3III), 77.99 (CH), 80.39 (CH), 81.55 (CH), 81.60 (2 × CH), 
81.67 (CH), 82.02 (CH), 82.06 (CH), 82.15 (CH), 82.17 (CH), 82.20 (CH), 82.34 (CH), 82.68 
(CH), 82.84 (CH), 83.13 (CH), 97.70 (CH, C1III), 98.39 (CH, C1VII), 99.67 (CH), 99.70 (CH), 
99.82 (CH), 100.24 (CH), 101.71 (CH), 104.92 (C, C5III), 105.15 (C, C5VII), 170.08 (C), 170.14 
(C); MS (ESI+-TOF): m/z (%) 1539 [(M + Na)+, 100]; HRMS (ESI+-TOF): m/z [M + Na]+ calcd 
for C65H112NaO39 1539.6678; found 1539.6642. Anal. calcd for C65H112O39: C, 51.44; H, 7.44. 
Found: C, 51.49; H, 7.60. 
Oxidative HAT of 2I-VI,3I-VI,6II,III,V,VI-hexadeca-O-methyl-D-cyclomaltohexaose (14). Method A: 
A solution of alcohol 1425,29 (90 mg, 0.075 mmol) in dry CH2Cl2 (3 mL) containing DIB (53 mg, 
0.165 mmol) and I2 (9.5 mg, 0.038 mmol) was stirred under nitrogen at 26 
oC for 1.5 h while 
irradiated with two 80 W tungsten-filament lamps. The reaction mixture was then directly loaded 










glucopyranosyl-ĺ-2,3,6-tri-O-methyl-D-D-glucopyranosyl (16) (17.5 mg, 0.015 mmol, 19%). 
Compound 15: Crystalline solid m.p. 250±252 qC (from n-hexane±EtOAc); [D]D +133.0 (c 1.176, 
CHCl3); IR (film): 2929, 1454, 1365, 1139, 1109, 1063 cm
±1; 1H NMR (500 MHz, CDCl3): G 3.14 
(dd, J = 9.1, 3.5 Hz, 2H), 3.20 (dd, J = 9.5, 3.5 Hz, 2H), 3.25 (dd, J = 9.8, 3.5 Hz, 2H), 3.368 (s, 
6H), 3.369 (s, 6H), 3.47 (s, 6H), 3.48 (s, 6H), 3.50 (s, 6H), 3.53 (dd, J = 9.5, 9.5 Hz, 2H), 3.61 (s, 
12H), 3.69 (dd, J = 9.3, 9.3 Hz, 2H), 3.74 (s, 6H), 3.77 (dd, J = 9.5, 9.5 Hz, 2H), 3.93 (d, J = 9.5 
Hz, 2H), 3.98 (d, J = 9.8 Hz, 2H), 4.99 (d, J = 3.8 Hz, 2H), 5.02 (d, J = 3.5 Hz, 2H), 5.19 (d, J = 
3.2 Hz, 2H); 13C NMR (125.7 MHz, CDCl3): G 57.62 (2 × CH3), 57.80 (2 × CH3), 58.13 (2 × CH3), 
58.98 (2 × CH3), 59.14 (2 × CH3), 61.28 (2 × CH3), 62.06 (2 × CH3), 62.14 (2 × CH3), 64.01 (2 × 
CH2), 66.49 (2 × CH), 70.69 (2 × CH2), 70.91 (2 × CH), 72.25 (2 × CH2), 78.32 (2 × CH), 80.38 
(2 × CH), 80.67 (2 × CH), 80.83 (2 × CH), 81.24 (2 × CH), 81.42 (2 × CH), 81.73 (2 × CH), 82.07 
(2 × CH), 82.21 (2 × CH), 97.28 (2 × CH), 98.63 (2 × CH), 99.13 (2 × CH), 100.37 (2 × C); MS 
(ESI+-TOF): m/z (%) 1215 [(M + Na)+, 100]; HRMS (ESI+-TOF): m/z [M + Na]+ calcd for 
C52H88NaO30 1215.5258; found 1215.5253. Anal. calcd for C52H88O30: C, 52.34; H, 7.43. Found: 
C, 52.41; H, 7.26. Compound 16: colorless oil, [D]D +108.2 (c 1.48, CHCl3); IR (film): 3475, 2929, 
1454, 1365, 1141, 1107, 1046 cm±1; 1H NMR (500 MHz, CDCl3): G 3.12±3.21 (m, 5H), 3.25 (dd, 
J = 9.8, 3.2 Hz, 1H), 3.36 (s, 3H), 3.37 (s, 3H), 3.379 (s, 3H), 3.380 (s, 3H), 3.47 (s, 3H), 3.47 (s, 
6H), 3.48 (s, 3H), 3.50 (s, 3H), 3.53 (s, 3H), 3.60 (s, 3H), 3.61 (s, 3H), 3.618 (s, 3H), 3.620 (s, 3H), 
3.71 (s, 3H), 3.73 (s, 3H), 4.96 (d, J = 3.5 Hz, 1H), 4.97 (d, J = 3.5 Hz, 1H), 5.03 (d, J = 3.5 Hz, 
1H), 5.04 (d, J = 3.5 Hz, 1H), 5.16 (d, J = 3.8 Hz, 1H), 5.19 (d, J = 3.5 Hz, 1H); 13C NMR (125.7 
MHz, CDCl3): G 57.65 (CH3), 57.83 (CH3), 57.85 (CH3), 57.86 (CH3), 58.39 (CH3), 58.72 (CH3), 
59.07 (3 × CH3), 59.09 (CH3), 61.25 (2 × CH3), 61.64 (CH3), 61.89 (CH3), 61.95 (CH2), 61.98 
(CH3), 62.25 (CH3), 64.05 (CH2), 66.40 (CH), 70.95 (CH2), 71.03 (CH), 71.14 (CH), 71.39 (CH2), 
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71.81 (CH), 72.03 (CH2), 72.07 (CH2), 72.10 (CH), 78.18 (CH), 80.09 (CH), 80.37 (CH), 80.46 
(CH), 80.75 (CH), 80.83 (CH), 80.86 (CH), 81.26 (CH), 81.33 (CH), 81.50 (CH), 81.61 (CH), 
81.65 (CH), 81.79 (CH), 81.96 (CH), 82.14 (CH), 82.45 (CH), 82.59 (CH), 82.78 (CH), 97.30 
(CH), 97.97 (CH), 98.34 (CH), 99.39 (2 × CH), 99.52 (CH), 100.79 (C); MS (ESI+-TOF): m/z (%) 
1217 [(M + Na)+, 100]; HRMS (ESI+-TOF): m/z [M + Na]+ calcd for C52H90NaO30 1217.5415; 
found 1217.5419. Anal. calcd for C52H90O30: C, 52.25; H, 7.59. Found: C, 52.33; H, 7.37. 
Method B: A solution of alcohol 14 (45 mg, 0.038 mmol) in dry CH2Cl2 (1.5 mL) containing 
DIB (30 mg, 0.095 mmol) and I2 (14.5 mg, 0.057 mmol) was stirred under nitrogen at 28 
oC for 
1.5 h while irradiated with two 80 W tungsten-filament lamps. The reaction mixture was then 
directly loaded onto a silica gel (TLC Silica gel 60 F254, scraped from Merck Aluminum sheets) 
column chromatography (hexanes±DFHWRQHĺWRJLYH15 (13 mg, 0.011 mmol, 29%) and 
16 (7.2 mg, 0.006 mmol, 16%). 
Method C: A solution of alcohol 14 (47 mg, 0.039 mmol) in dry CH2Cl2 (1.6 mL) containing 
DIB (37.7 mg, 0.117 mmol) and I2 (16.8 mg, 0.066 mmol) was stirred under nitrogen at 28 oC for 
1.5 h while irradiated with two 80 W tungsten-filament lamps. The reaction mixture was then 
directly loaded onto a silica gel (TLC Silica gel 60 F254, scraped from Merck Aluminum sheets) 
column chromatography (hexanes±acetone, 65:35) to give 15 (15.9 mg, 0.013 mmol, 34%). 
Oxidative HAT of mono-trioxocane alcohol (16). A solution of alcohol 16 (12 mg, 0.01 mmol) 
in dry CH2Cl2 (0.45 mL) containing DIB (7 mg, 0.022 mmol) and I2 (1.3 mg, 0.005 mmol) was 
stirred under nitrogen at 28 oC for 2 h while irradiated with two 80 W tungsten-filament lamps. The 
reaction mixture was then directly loaded onto a silica gel (TLC Silica gel 60 F254, scraped from Merck 
Aluminum sheets) column chromatography (hexanes±acetone, 65:35) to give bis(trioxocane) 15 (6 
mg, 0.005 mmol, 50%). 
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Oxidative HAT of 2I-VII,3I-VII,6II,IV-VII-nonadeca-O-methyl-E-cyclomaltoheptaose (17). A solution 
of alcohol 1717a (119 mg, 0.085 mmol) in dry CH2Cl2 (3.5 mL) containing DIB (60.2 mg, 0.187 
mmol) and I2 (28 mg, 0.110 mmol) was stirred under nitrogen at 30 
oC for 2.5 h while irradiated 
with two 80 W tungsten-filament lamps. The reaction mixture was then directly loaded onto a silica 
gel (TLC Silica gel 60 F254, scraped from Merck Aluminum sheets) column chromatography (CHCl3±
0H2+ĺWRJLYHWKHDFHW\OGHULYDWLYH18 as an inseparable mixture of positional isomers 
(26.1 mg, 0.018 mmol, 21%, 70:30), cyclo-(5R)-5VII-O-acetyl-2,3,6-tri-O-methyl-D-D-xylo-hexos-
5-ulopyranosyl-ĺ-2,3-di-O-methyl-D-D-glucopyranosyl-ĺ-(5R)-5II-O-acetyl-2,3,6-tri-
O-methyl-D-D-xylo-hexos-5-ulopyranosyl-ĺ-2,3-di-O-methyl-D-D-glucopyranosyl->ĺ-












glucopyranosyl]3 (22) (6.9 mg, 0.005 mmol, 6%). Compound 18: colorless oil, IR (film): 3516, 
2933, 1732, 1455, 1368, 1105, 1036 cm±1; 1H NMR (500 MHz, CDCl3) (only the major isomer is 
shown): G 2.06 (s, 3H), 3.18 (m, 6H), 3.30 (dd, J
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3.373 (s, 3H), 3.39 (s, 3H), 3.40 (s, 3H), 3.43 (s, 3H), 3.45 (s, 3H), 3.482 (s, 3H), 3.483 (s, 3H), 
3.49 (s, 3H), 3.50 (s, 3H), 3.54 (s, 3H), 3.59 (s, 3H), 3.61 (s, 3H), 3.617 (s, 3H), 3.621 (s, 3H), 
3.627 (s, 3H), 3.633 (s, 3H), 3.64 (s, 3H), 3.94 (d, J = 9.8 Hz, 1H), 4.02 (d, J = 9.8 Hz, 1H), 4.05 
(d, J = 1.9 Hz, 1H), 4.18 (dd, J = 2.4, 2.4 Hz, 1H), 4.30 (dd, J = 11.2, 5.8 Hz, 1H), 5.01 (d, J = 3.2 
Hz, 1H), 5.037 (d, J = 3.4 Hz, 1H), 5.044 (d, J = 3.8 Hz, 1H), 5.079 (d, J = 4.1 Hz, 1H), 5.087 (d, 
J = 4.1 Hz, 1H), 5.12 (d, J = 1.9 Hz, 1H), 5.16 (d, J = 3.8 Hz, 1H); 1H NMR (500 MHz, CDCl3, 
1D-ROESY, irradiation at 2.06 ppm): G 5.12 (d, J = 1.9 Hz, 1H, H1VII); 13C NMR (125.7 MHz, 
CDCl3) (only the major isomer is shown): G 22.10 (CH3), 57.21 (CH3), 57.50 (CH3), 58.24 (CH3), 
58.53 (CH3), 58.57 (CH3), 58.88 (2 × CH3), 58.91 (CH3), 58.95 (CH3), 58.97 (2 × CH3), 59.01 
(CH3), 59.20 (CH3), 60.20 (CH2), 61.22 (CH3), 61.23 (CH3), 61.37 (CH3), 61.41 (CH3), 61.50 
(CH3), 61.67 (CH3), 61.82 (CH2), 70.33 (CH2), 70.33 (CH), 71.02 (2 × CH), 71.02 (CH2), 71.13 (2 
× CH2), 71.14 (2 × CH), 71.27 (CH2), 71.42 (CH), 72.21 (CH), 75.42 (CH), 76.81 (CH), 79.73 
(CH), 80.17 (CH), 80.31 (CH), 81.13 (2 × CH), 81.52 (CH), 81.62 (CH), 81.66 (2 × CH), 81.73 (2 
× CH), 81.90 (CH), 82.02 (CH), 82.30 (CH), 82.33 (CH), 82.44 (2 × CH), 83.67 (CH), 97.69 (CH), 
99.10 (CH), 99.35 (CH), 99.37 (CH), 99.41 (CH), 99.62 (CH), 100.10 (CH), 104.99 (C), 170.18 
(C); MS (ESI+-TOF): m/z (%) 1481 [(M + Na)+, 100]; HRMS (ESI+-TOF): m/z [M + Na]+ calcd 
for C63H110NaO37 1481.6624; found 1481.6647. Anal. calcd for C63H110O37: C, 51.84; H, 7.60. 
Found: C, 51.60; H, 7.45. Compound 19: colorless oil, [D]D +118.9 (c 1.34, CHCl3); IR (film): 3521, 
2928, 1732, 1455, 1368, 1195, 1105, 1041 cm±1; 1H NMR (500 MHz, CDCl3): G 2.04 (s, 3H), 2.05 
(s, 3H), 3.16 (dd, J = 9.8, 3.8 Hz, 2H), 3.17 (dd, J = 9.5, 3.2 Hz, 1H), 3.21 (dd, J = 9.8, 3.5 Hz, 
1H), 3.25 (dd, J = 9.9, 3.3 Hz, 1H), 3.30 (dd, J = 9.8, 9.8 Hz, 1H), 3.32 (dd, J = 2.2, 2.2 Hz, 1H, 
H2), 3.36 (s, 3H), 3.37 (s, 3H), 3.38 (s, 3H), 3.39 (s, 3H), 3.40 (s, 3H), 3.41 (s, 3H), 3.42 (s, 3H), 
3.46 (s, 3H), 3.47 (s, 3H), 3.479 (s, 3H), 3.482 (s, 3H), 3.53 (s, 3H), 3.54 (s, 3H), 3.586 (s, 3H), 
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3.593 (s, 3H), 3.60 (s, 3H), 3.61 (s, 3H), 3.62 (s, 3H), 3.64 (s, 3H), 4.01 (br d, J = 3.2 Hz, 1H, H4), 
4.04 (dd, J = 2.5, 2.5 Hz, 1H, H3), 4.06 (d, J = 2.2 Hz, 1H, H4), 4.18 (dd, J = 2.5, 2.5 Hz, 1H, H3), 
4.99 (d, J = 3.2 Hz, 1H), 5.00 (d, J = 4.1 Hz, 1H), 5.07 (d, J = 2.2 Hz, 1H, H1), 5.079 (d, J = 3.5 
Hz, 1H), 5.082 (d, J = 3.5 Hz, 1H), 5.10 (d, J = 3.5 Hz, 1H), 5.12 (d, J = 1.9 Hz, 1H, H1); 1H NMR 
(500 MHz, C6D6): G 1.68 (s, 3H), 1.84 (s, 3H), 3.01 (dd, J = 9.1, 2.8 Hz, 1H), 3.10 (dd, J = 9.5, 3.5 
Hz, 1H), 3.14 (s, 3H), 3.21 (s, 3H), 3.22 (s, 3H), 3.22 (s, 3H), 3.24 (s, 3H), 3.28 (s, 3H), 3.31 (s, 
3H), 3.35 (s, 3H), 3.36 (s, 3H), 3.40 (s, 3H), 3.41 (s, 6H), 3.42 (s, 3H), 3.48 (s, 3H), 3.65 (s, 3H), 
3.66 (s, 6H), 3.69 (s, 3H), 3.79 (s, 3H), 5.00 (d, J = 2.8 Hz, 1H), 5.14 (d, J = 3.2 Hz, 1H), 5.18 (d, 
J = 3.2 Hz, 1H), 5.20 (d, J = 3.5 Hz, 1H), 5.32 (d, J = 3.8 Hz, 1H), 5.48 (d, J = 2.5 Hz, 1H), 5.53 
(d, J = 2.2 Hz, 1H); 1H NMR (500 MHz, CDCl3, 1D-TOCSY, irradiation at H1
II or VII, 5.12 ppm): 
G 3.42 (br s, 1H, H2), 4.05 (br s, 1H, H4), 4.22 (br s, 1H, H3); 1H NMR (500 MHz, CDCl3, 1D-
TOCSY, irradiation at H1VII or II, 5.07 ppm): G 3.36 (br s, 1H, H2), 4.08 (dd, J = 2.5, 2.5 Hz, 1H, 
H3), 4.09 (br s, 1H, H4); 1H NMR (500 MHz, CDCl3, 2D-ROESY): both acetates show NOE 
interactions with their respective anomeric hydrogens: H1VII and H1II; 13C NMR (125.7 MHz, 
CDCl3): G 22.05 (CH3), 22.08 (CH3), 57.33 (CH3), 57.37 (CH3), 57.58 (CH3), 58.20 (CH3), 58.38 
(CH3), 58.71 (CH3), 58.93 (CH3), 58.96 (5 × CH3), 59.36 (CH3), 59.94 (CH2), 60.06 (CH3), 60.36 
(CH2), 61.14 (CH3), 61.27 (CH3), 61.45 (2 × CH3), 61.65 (CH3), 70.08 (CH), 70.34 (CH2), 70.57 
(CH2), 70.66 (CH2), 70.71 (CH2), 70.88 (CH2), 70.98 (CH), 71.14 (CH), 71.30 (CH), 71.51 (CH), 
71.86 (CH), 72.43 (CH), 75.96 (CH), 77.02 (CH), 77.14 (CH), 77.56 (CH), 78.17 (CH), 80.10 
(CH), 81.36 (CH), 81.39 (CH), 81.49 (CH), 81.58 (CH), 81.63 (CH), 81.88 (CH), 81.99 (CH), 
82.01 (CH), 82.08 (CH), 82.51 (CH), 82.74 (CH), 83.03 (CH), 83.12 (CH), 97.80 (CH), 97.82 
(CH), 99.46 (2 × CH), 99.59 (CH), 100.49 (CH), 101.81 (CH), 104.33 (C), 105.18 (C), 170.01 (C), 
170.12 (C); MS (ESI+-TOF): m/z (%) 1539 [(M + Na)+, 100]; HRMS (ESI+-TOF): m/z [M + Na]+ 
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calcd for C65H112NaO39 1539.6678; found 1539.6660. Anal. calcd for C65H112O39: C, 51.44; H, 
7.44. Found: C, 51.48; H, 7.64. Compound 20: colorless oil, [D]D +123.5 (c 0.96, CHCl3); IR (film): 
3540, 2928, 1732, 1455, 1368, 1138, 1105, 1046 cm±1; 1H NMR (500 MHz, CDCl3): G 2.05 (s, 
3H), 3.24 (dd, J = 10.1, 3.5 Hz, 1H), 3.25 (dd, J = 10.1, 3.3 Hz, 1H), 3.35 (s, 3H), 3.37 (s, 3H), 
3.38 (s, 3H), 3.39 (s, 3H), 3.40 (s, 3H), 3.42 (s, 3H), 3.45 (s, 3H), 3.477 (s, 3H), 3.480 (s, 3H), 3.49 
(s, 3H), 3.50 (s, 3H), 3.53 (s, 3H), 3.60 (s, 3H), 3.61 (s, 6H), 3.63 (s, 3H), 3.66 (s, 3H), 3.67 (s, 
3H), 3.68 (s, 3H), 3.90 (d, J = 8.8 Hz, 1H), 4.21 (m, 1H), 4.23 (dd, J = 2.5, 2.5 Hz, 1H), 4.27 (br 
dd, J = 11.7, 6.3 Hz, 1H), 4.98 (d, J = 3.2 Hz, 1H), 5.00 (d, J = 3.2 Hz, 1H), 5.04 (d, J = 3.5 Hz, 
1H), 5.09 (d, J = 4.1 Hz, 1H), 5.13 (d, J = 3.5 Hz, 1H), 5.15 (d, J = 1.9 Hz, 1H), 5.17 (d, J = 3.5 
Hz, 1H); 1H NMR (500 MHz, CDCl3, 1D-TOCSY, irradiation at H1
II, 5.17 ppm): G 3.24 (dd, J = 
9.9, 3.7 Hz, 1H, H2II), 3.64 (dd, J = 9.2, 9.2 Hz, 1H, H3II), 3.90 (d, J = 9.0 Hz, 1H, H4II); 1H NMR 
(500 MHz, CDCl3, 1D-TOCSY, irradiation at H1
I, 5.00 ppm): G 3.25 (dd, J = 9.3, 3.0 Hz, 1H, H2I), 
3.54 (m, 1H, H6I), 3.59 (dd, J = 9.4, 9.4 Hz, 1H, H3I), 3.63 (dd, J = 9.1, 9.1 Hz, 1H, H4I), 4.21 (br 
d, J = 10 Hz, 1H, H5I), 4.27 (br dd, J = 12.6, 5.4 Hz, 1H, H6I); 1H NMR (500 MHz, CDCl3, 1D-
ROESY, irradiation at H1I, 5.00 ppm): G 3.25 (dd, J = 9.3, 3.3 Hz, 1H, H2I), 3.90 (d, J = 9.1 Hz, 
1H, H4II); 13C NMR (125.7 MHz, CDCl3): G 22.05 (CH3), 57.42 (CH3), 57.56 (2 × CH3), 58.30 
(CH3), 58.39 (CH3), 58.88 (CH3), 58.90 (CH3), 58.93 (CH3), 58.98 (CH3), 59.01 (CH3), 59.04 (3 × 
CH3), 60.13 (CH2), 61.13 (2 × CH3), 61.40 (CH3), 61.61 (CH3), 61.69 (CH3), 62.06 (CH3), 63.85 
(CH2), 67.06 (CH), 70.48 (CH2), 70.74 (CH), 70.77 (CH2), 70.90 (CH), 70.90 (CH2), 71.03 (CH2), 
71.08 (CH), 71.43 (CH), 72.16 (CH2), 72.83 (CH), 75.62 (CH), 76.57 (CH), 78.46 (CH), 79.02 
(CH), 80.24 (CH), 80.32 (CH), 80.35 (CH), 80.63 (CH), 81.03 (CH), 81.48 (CH), 81.57 (CH), 
81.69 (2 × CH), 81.73 (CH), 81.77 (2 × CH), 82.21 (CH), 82.71 (CH), 83.09 (CH), 83.38 (CH), 
97.20 (CH), 97.31 (CH), 98.31 (CH), 98.45 (CH), 99.61 (CH), 100.31 (CH), 100.35 (C), 102.03 
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(CH), 105.25 (C), 170.26 (C); MS (ESI+-TOF): m/z (%) 1479 [(M + Na)+, 100]; HRMS (ESI+-
TOF): m/z [M + Na]+ calcd for C63H108NaO37 1479.6467; found 1479.6483. Anal. calcd for 
C63H108O37: C, 51.92; H, 7.47. Found: C, 52.16; H, 7.75. Compound 21: colorless oil, [D]D +110.6 
(c 0.36, CHCl3); IR (film): 3526, 2928, 1732, 1455, 1368, 1143, 1107, 1046 cm
±1; 1H NMR (500 
MHz, CDCl3): G 2.06 (s, 3H), 3.12 (dd, J = 10.1, 3.5 Hz, 1H), 3.15 (dd, J = 9.1, 3.2 Hz, 1H), 3.20 
(dd, J = 9.8, 3.8 Hz, 1H), 3.35 (s, 3H), 3.37 (s, 9H), 3.40 (s, 3H), 3.43 (s, 3H), 3.46 (s, 3H), 3.47 
(s, 6H), 3.48 (s, 3H), 3.51 (s, 3H), 3.56 (s, 3H), 3.61 (s, 9H), 3.64 (s, 3H), 3.64 (s, 3H), 3.66 (s, 
3H), 3.67 (s, 3H), 3.82 (dd, J = 10.7, 10.7 Hz, 1H, H6I), 3.95 (d, J = 9.8 Hz, 1H, H6II), 4.06 (d, J = 
9.8 Hz, 1H, H6II), 4.11 (br s, 2H, H4II and H3II), 4.37 (ddd, J = 12.0, 6.6, 1.6 Hz, 1H, H6III), 5.01 
(d, J = 3.2 Hz, 1H), 5.03 (d, J = 3.5 Hz, 1H), 5.04 (d, J = 4.4 Hz, 1H), 5.08 (d, J = 1.9 Hz, 1H), 
5.163 (d, J = 3.2 Hz, 1H), 5.166 (d, J = 2.9 Hz, 1H), 5.21 (d, J = 3.8 Hz, 1H); 1H NMR (500 MHz, 
CDCl3, 1D-TOCSY, irradiation at H1
II, 5.08 ppm): G 3.24 (br s, 1H, H2II), 4.109 (dd, J = 2.9, 2.9 
Hz, 1H, H3II), 4.111 (d, J = 2.9 Hz, 1H, H4II); 1H NMR (500 MHz, CDCl3, 1D-TOCSY, irradiation 
at H1I, 5.01 ppm): G 3.16 (br d, J = 10.1 Hz, 1H, H2I), 3.42 (dd, J = 9.3, 9.3 Hz, 1H, H3I), 3.46 (dd, 
J = 9.0, 9.0 Hz, 1H, H4I), 3.65 (m, 1H, H5I), 3.98 (dd, J = 9.2, 2.8 Hz, 1H, H6I); 1H NMR (500 
MHz, CDCl3, 1D-ROESY, irradiation at H1
I, 5.01 ppm): G 4.11 (d, J = 2.9 Hz, 1H, H4II); 13C NMR 
(125.7 MHz, CDCl3): G 22.13 (CH3), 57.08 (CH3), 57.54 (CH3), 57.84 (CH3), 58.14 (CH3), 58.20 
(CH3), 58.84 (CH3), 58.86 (CH3), 58.89 (CH3), 58.98 (CH3), 59.04 (CH3), 59.10 (CH3), 59.14 
(CH3), 59.89 (CH3), 60.37 (CH2), 60.90 (CH3), 61.25 (CH3), 61.35 (CH3), 61.67 (CH3), 61.73 
(CH3), 62.10 (CH3), 63.91 (CH2), 67.13 (CH), 69.00 (CH), 70.29 (CH2), 70.45 (CH), 70.95 (CH), 
70.95 (CH2), 71.33 (CH), 71.47 (CH2), 71.54 (CH), 71.54 (CH2), 71.82 (CH2), 75.65 (CH), 76.98 
(CH), 77.20 (CH), 77.55 (CH), 79.22 (CH), 79.90 (CH), 80.36 (CH), 80.86 (CH), 80.96 (CH), 
80.99 (CH), 81.07 (CH), 81.36 (CH), 81.79 (CH), 81.87 (CH), 81.95 (CH), 81.97 (CH), 82.34 
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(CH), 82.87 (CH), 83.09 (CH), 83.45 (CH), 97.08 (CH), 97.66 (CH), 98.06 (CH), 98.21 (CH), 
98.77 (CH), 99.10 (CH), 99.28 (CH), 100.76 (C), 105.18 (C), 170.26 (C); MS (ESI+-TOF): m/z 
(%) 1479 [(M + Na)+, 100]; HRMS (ESI+-TOF): m/z [M + Na]+ calcd for C63H108NaO37 1479.6467; 
found 1479.6459. Anal. calcd for C63H108O37: C, 51.92; H, 7.47. Found: C, 52.14; H, 7.39. 
Compound 22: colorless oil, [D]D +116.9 (c 0.46, CHCl3); IR (film): 2928, 1455, 1370, 1159, 1102, 
1046 cm±1; 1H NMR (500 MHz, CDCl3): G 3.099 (d, J = 9.8 Hz, 1H), 3.10 (dd, J = 9.5, 3.5 Hz, 
1H), 3.24 (dd, J = 9.8, 9.8 Hz, 1H), 3.30 (dd, J = 9.5, 3.5 Hz, 1H), 3.34 (s, 3H), 3.37 (s, 3H), 3.38 
(s, 6H), 3.39 (s, 3H), 3.47 (s, 6H), 3.48 (s, 3H), 3.49 (s, 3H), 3.54 (s, 3H), 3.57 (s, 3H), 3.575 (s, 
3H), 3.582 (s, 3H), 3.59 (s, 6H), 3.618 (s, 3H), 3.619 (s, 3H), 3.70 (s, 3H), 3.74 (s, 3H), 4.24 (dd, 
J = 9.1, 7.9 Hz, 1H), 4.30 (ddd, J = 10.7, 7.9, 7.9 Hz, 1H), 5.02 (d, J = 3.5 Hz, 1H), 5.06 (d, J = 3.5 
Hz, 1H), 5.09 (d, J = 3.2 Hz, 1H), 5.094 (d, J = 3.2 Hz, 1H), 5.23 (d, J = 3.5 Hz, 1H), 5.30 (d, J = 
3.8 Hz, 1H); 1H NMR (500 MHz, CDCl3, 1D-TOCSY, irradiation at H1
III, 5.30 ppm): G 3.20 (dd, 
J = 9.6, 3.8 Hz, 1H, H2III), 3.59 (dd, J = 9.2, 9.2 Hz, 1H, H3III), 3.64 (dd, J = 9.4, 9.4 Hz, 1H, H6III), 
3.68 (dd, J = 9.2, 9.2 Hz, 1H, H4III), 4.24 (dd, J = 9.0, 9.0 Hz, 1H, H6III), 3.99 (ddd, J = 10.4, 8.0, 
8.0 Hz, 1H, H5III); 1H NMR (500 MHz, CDCl3, 1D-TOCSY, irradiation at H1
I, 5.23 ppm): G 3.31 
(dd, J = 9.3, 3.9 Hz, 1H, H2I), 3.78 (dd, J = 9.6, 9.6 Hz, 1H, H3I), 3.85 (d, J = 9.5 Hz, 1H, H4I); 1H 
NMR (500 MHz, CDCl3, 1D-ROESY, irradiation at H1
III, 5.30 ppm): G 3.21 (dd, J = 9.7, 3.8 Hz, 
1H, H2III), 3.60 (dd, J = 9.2, 9.2 Hz, 1H, H4IV); 13C NMR (125.7 MHz, CDCl3): G 57.84 (CH3), 
57.88 (CH3), 58.02 (CH3), 58.26 (CH3), 58.34 (CH3), 58.81 (CH3), 58.83 (CH3), 58.94 (CH3), 58.98 
(CH3), 59.38 (CH3), 59.89 (CH3), 60.75 (2 × CH3), 61.01 (CH3), 61.10 (CH3), 61.50 (CH3), 61.85 
(CH3), 61.96 (CH3), 62.28 (CH3), 62.53 (CH), 62.79 (CH2), 65.12 (CH2), 66.50 (CH), 70.27 (CH), 
70.96 (CH2), 71.08 (CH), 71.11 (CH), 71.16 (CH2), 71.42 (CH2), 71.73 (CH2), 71.94 (CH), 72.18 
(CH2), 74.72 (CH), 77.17 (CH), 77.61 (CH), 78.77 (CH), 79.92 (CH), 80.57 (CH), 80.83 (CH), 
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81.03 (CH), 81.14 (CH), 81.31 (CH), 81.46 (CH), 81.47 (CH), 81.90 (CH), 82.00 (CH), 82.07 
(CH), 82.27 (CH), 82.48 (CH), 82.60 (CH), 83.37 (CH), 83.56 (CH), 83.91 (CH), 96.87 (CH), 
99.44 (2 × CH), 99.86 (CH), 100.34 (CH), 100.47 (CH), 101.28 (C), 111.08 (C); MS (ESI+-TOF): 
m/z (%) 1419 [(M + Na)+, 100]; HRMS (ESI+-TOF): m/z [M + Na]+ calcd for C61H104NaO35 
1419.6256; found 1419.6287. Anal. calcd for C61H104O35: C, 52.43; H, 7.50. Found: C, 52.18; H, 
7.74. 
Oxidative HAT of 2I-VI,3I-VI,6II,IV-VI-hexadeca-O-methyl-D-cyclomaltohexaose (23). A solution of 
alcohol 23 (120 mg, 0.10 mmol) in dry CH2Cl2 (4 mL) containing DIB (71 mg, 0.22 mmol) and I2 
(25.4 mg, 0.10 mmol) was stirred under nitrogen at 28 oC for 1.5 h while irradiated with two 80 W 
tungsten-filament lamps. The reaction mixture was then directly loaded onto a silica gel (TLC Silica 
gel 60 F254, scraped from Merck Aluminum sheets) column chromatography (hexanes±acetone, 
ĺ WR JLYH cyclo-5II,6III-anhydro-(5IIR)-(2,3,6-tri-O-methyl-D-D-xylo-hexos-5-
ulopyranosyl)-ĺ-2,3-di-O-methyl-D-D-glucopyranosyl->ĺ-2,3,6-tri-O-methyl-D-D-
glucopyranosyl]2-ĺ-5VI,6I-anhydro-(5VIR)-(2,3,6-tri-O-methyl-D-D-xylo-hexos-5-
ulopyranosyl)-ĺ-2,3-di-O-methyl-D-D-glucopyranosyl (24) (33.4 mg, 0.028, 28%), cyclo-
5II,6III-anhydro-(5R)-(2,3,6-tri-O-methyl-D-D-xylo-hexos-5-ulopyranosyl)-ĺ-2,3-di-O-
methyl-D-D-glucopyranosyl->ĺ-2,3,6-tri-O-methyl-D-D-glucopyranosyl]3-ĺ-2,3-di-O-
methyl-D-D-glucopyranosyl (25) (22 mg, 0.018 mmol, 18%), and cyclo-5VI,6I-anhydro-(5VIR)-
(2,3,6-tri-O-methyl-D-D-xylo-hexos-5-ulopyranosyl)-ĺ-2,3-di-O-methyl-D-D-
glucopyranosyl)-ĺ-2,3,6-tri-O-methyl-D-D-glucopyranosyl-ĺ-2,3-di-O-methyl-D-D-
glucopyranosyl->ĺ-2,3,6-tri-O-methyl-D-D-glucopyranosyl]2 (26) (24 mg, 0.020 mmol, 
20%). Compound 24: colorless oil, [D]D +124.1 (c 1.70, CHCl3); IR (film): 2928, 1453, 1368, 1140, 
1107, 1060 cm±1; 1H NMR (500 MHz, CDCl3): G 3.14 (m, 4H), 3.22 (dd, J = 9.1, 3.8 Hz, 1H), 3.24 
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(dd, J = 9.5, 3.5 Hz, 1H), 3.35 (s, 3H), 3.36 (s, 6H), 3.37 (s, 3H), 3.466 (s, 3H), 3.469 (s, 3H), 3.485 
(s, 3H), 3.491 (s, 6H), 3.494 (s, 3H), 3.60 (s, 3H), 3.62 (s, 3H), 3.63 (s, 3H), 3.68 (s, 3H), 3.70 (s, 
3H), 3.71 (s, 3H), 4.98 (d, J = 3.8 Hz, 1H), 5.00 (d, J = 3.2 Hz, 2H), 5.03 (d, J = 3.8 Hz, 1H), 5.15 
(d, J = 3.5 Hz, 1H), 5.16 (d, J = 3.5 Hz, 1H); 13C NMR (125.7 MHz, CDCl3): G 57.59 (CH3), 57.70 
(CH3), 57.92 (CH3), 58.11 (CH3), 58.38 (CH3), 58.62 (CH3), 58.76 (CH3), 58.95 (CH3), 59.09 
(CH3), 59.14 (CH3), 61.27 (CH3), 61.32 (CH3), 61.52 (CH3), 61.86 (CH3), 61.94 (CH3), 62.14 
(CH3), 63.44 (CH2), 63.91 (CH2), 65.60 (CH), 66.37 (CH), 70.48 (CH), 71.03 (CH), 71.57 (CH2), 
71.67 (CH2), 71.81 (CH2), 72.90 (CH2), 78.05 (CH), 78.23 (CH), 79.77 (CH), 79.91 (CH), 80.07 
(CH), 80.74 (CH), 80.82 (CH), 80.97 (CH), 81.14 (CH), 81.16 (CH), 81.19 (CH), 81.23 (CH), 
81.34 (CH), 81.79 (CH), 82.37 (CH), 82.44 (CH), 82.60 (CH), 83.29 (CH), 96.36 (CH), 96.48 
(CH), 97.37 (CH), 97.53 (CH), 100.15 (CH), 100.21 (CH), 100.47 (C), 100.78 (C); MS (ESI+-
TOF): m/z (%) 1215 [(M + Na)+, 100]; HRMS (ESI+-TOF): m/z [M + Na]+ calcd for C52H88NaO30 
1215.5258; found 1215.5237. Anal. calcd for C52H88O30: C, 52.34; H, 7.43. Found: C, 52.42; H, 
7.43. Compound 25: colorless oil, [D]D +123.7 (c 1.81, CHCl3); IR (film): 3494, 2933, 1454, 1365, 
1109, 1039 cm±1; 1H NMR (500 MHz, CDCl3): G 3.11 (dd, J = 10.1, 3.5 Hz, 1H), 3.13 (dd, J = 
10.4, 3.5 Hz, 1H), 3.15 (dd, J = 9.8, 3.2 Hz, 1H), 3.18 (dd, J = 10.1, 3.5 Hz, 1H), 3.20 (dd, J = 9.8, 
3.5 Hz, 1H), 3.25 (dd, J = 9.6, 3.3 Hz, 1H), 3.35 (s, 3H), 3.369 (s, 3H), 3.371 (s, 3H), 3.38 (s, 3H), 
3.476 (s, 3H), 3.479 (s, 3H), 3.487 (s, 3H), 3.490 (s, 6H), 3.495 (s, 3H), 3.58 (s, 3H), 3.60 (s, 3H), 
3.638 (s, 3H), 3.644 (s, 3H), 3.70 (s, 3H), 3.71 (s, 3H), 4.98 (d, J = 3.8 Hz, 1H), 4.99 (d, J = 3.8 
Hz, 1H), 5.00 (d, J = 3.5 Hz, 1H), 5.01 (d, J = 3.5 Hz, 1H), 5.08 (d, J = 3.5 Hz, 1H), 5.17 (d, J = 
3.2 Hz, 1H); 13C NMR (125.7 MHz, CDCl3): G 57.71 (CH3), 57.84 (2 × CH3), 58.17 (CH3), 58.42 
(CH3), 58.49 (CH3), 58.95 (2 × CH3), 59.00 (CH3), 59.14 (CH3), 61.28 (CH3), 61.33 (CH3), 61.61 
(CH3), 61.90 (CH3), 61.94 (CH3), 62.06 (CH2), 62.20 (CH3), 63.76 (CH2), 66.25 (CH), 70.96 (CH), 
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71.05 (CH2), 71.40 (CH), 71.52 (CH2), 71.62 (CH), 72.12 (CH), 72.12 (CH2), 72.22 (CH2), 78.45 
(CH), 80.44 (2 × CH), 80.81 (CH), 80.94 (CH), 81.01 (CH), 81.06 (CH), 81.19 (CH), 81.35 (CH), 
81.44 (CH), 81.76 (CH), 81.93 (CH), 82.09 (CH), 82.12 (CH), 82.33 (2 × CH), 82.55 (CH), 82.59 
(CH), 97.44 (CH), 97.80 (CH), 98.64 (CH), 99.10 (CH), 99.78 (CH), 100.04 (CH), 100.69 (C); MS 
(ESI+-TOF): m/z (%) 1217 [(M + Na)+, 100]; HRMS (ESI+-TOF): m/z [M + Na]+ calcd for 
C52H90NaO30 1217.5415; found 1217.5405. Anal. calcd for C52H90O30: C, 52.25; H, 7.59. Found: 
C, 51.98; H, 7.48. Compound 26: colorless oil, [D]D +112.0 (c 1.65, CHCl3); IR (film): 3475, 2933, 
1454, 1367, 1111, 1044 cm±1; 1H NMR (500 MHz, CDCl3): G 3.10 (dd, J = 10.1, 3.5 Hz, 1H), 3.13 
(dd, J = 10.1, 3.5 Hz, 1H), 3.15 (dd, J = 9.2, 3.8 Hz, 1H), 3.18 (dd, J = 9.8, 3.8 Hz, 1H), 3.19 (dd, 
J = 9.8, 3.2 Hz, 1H), 3.25 (dd, J = 9.6, 3.3 Hz, 1H), 3.35 (s, 3H), 3.37 (s, 3H), 3.37 (s, 3H), 3.38 (s, 
3H), 3.47 (s, 3H), 3.47 (s, 3H), 3.48 (s, 3H), 3.48 (s, 3H), 3.49 (s, 3H), 3.53 (s, 3H), 3.59 (s, 3H), 
3.60 (s, 3H), 3.63 (s, 3H), 3.63 (s, 3H), 3.70 (s, 3H), 3.74 (s, 3H), 4.96 (d, J = 3.8 Hz, 1H), 5.01 (d, 
J = 3.8 Hz, 1H), 5.03 (d, J = 3.5 Hz, 1H), 5.04 (d, J = 3.2 Hz, 1H), 5.07 (d, J = 3.5 Hz, 1H), 5.19 
(d, J = 3.5 Hz, 1H); 13C NMR (125.7 MHz, CDCl3): G 57.67 (CH3), 57.82 (CH3), 57.84 (CH3), 
57.99 (CH3), 58.39 (CH3), 58.47 (CH3), 58.80 (CH3), 59.00 (2 × CH3), 59.09 (CH3), 61.28 (CH3), 
61.50 (CH3), 61.54 (CH3), 61.93 (CH3), 61.97 (CH3), 62.25 (CH3), 62.48 (CH2), 63.86 (CH2), 66.28 
(CH), 70.87 (CH), 71.03 (CH), 71.10 (CH), 71.12 (CH2), 71.24 (CH2), 71.83 (CH2), 71.99 (CH2), 
72.77 (CH), 78.30 (CH), 80.46 (CH), 80.57 (CH), 80.73 (CH), 80.78 (CH), 81.02 (2 × CH), 81.31 
(CH), 81.42 (CH), 81.50 (CH), 81.75 (CH), 81.89 (CH), 81.97 (CH), 82.11 (CH), 82.30 (CH), 
82.50 (CH), 82.60 (CH), 82.70 (CH), 97.36 (CH), 97.75 (CH), 98.77 (CH), 99.57 (CH), 99.86 
(CH), 100.04 (CH), 100.80 (C); MS (ESI+-TOF): m/z (%) 1217 [(M + Na)+, 100]; HRMS (ESI+-
TOF): m/z [M + Na]+ calcd for C52H90NaO30 1217.5415; found 1217.5427. Anal. calcd for 





acetyl-2,3-di-O-methyl-D-D-glucopyranosyl (27). A solution of alcohol 25 (16.7 mg, 0.014 mmol) 
in dry pyridine (0.9 mL) containing Ac2O (0.3 mL) and DMAP (0.2 mg, 0.001 mmol) was stirred 
at room temperature for 16 h. The mixture was then poured into 10% aqueous HCl and extracted 
with CHCl3. The organic layer was washed with aqueous saturated NaHCO3, dried over Na2SO4 
and concentrated under reduced pressure. The residue was then purified by silica gel (TLC Silica 
gel 60 F254, scraped from Merck Aluminum sheets) column chromatography (CHCl3±MeOH, 
99.5:0.5) to give acetyl-trioxocane 27 (14.5 mg, 0.012 mmol, 84%) as a colorless oil: [D]D +113.2 (c 
1.45, CHCl3); IR (film): 2929, 1742, 1456, 1365, 1109, 1044 cm
±1; 1H NMR (500 MHz, CDCl3): 
G 2.07 (s, 3H), 3.19 (dd, J = 9.8, 3.2 Hz, 2H), 3.25 (dd, J = 9.8, 3.2 Hz, 1H), 3.35 (s, 3H), 3.37 (s, 
6H), 3.383 (s, 3H), 3.477 (s, 3H), 3.482 (s, 3H), 3.489 (s, 3H), 3.490 (s, 3H), 3.495 (s, 3H), 3.50 
(s, 3H), 3.59 (s, 3H), 3.60 (s, 3H), 3.63 (s, 6H), 3.70 (s, 3H), 3.72 (s, 3H), 4.08 (dd, J = 11.2, 3.0 
Hz, 1H), 4.18 (dd, J = 12.0, 4.1 Hz, 1H), 4.38 (dd, J = 12.0, 1.6 Hz, 1H), 5.02 (m, 3H), 5.03 (d, J 
= 3.2 Hz, 1H), 5.06 (d, J = 3.2 Hz, 1H), 5.19 (d, J = 3.5 Hz, 1H); 1H NMR (500 MHz, C6D6): G 
1.87 (s, 3H), 3.26 (s, 6H), 3.28 (s, 3H), 3.29 (s, 3H), 3.29 (s, 3H), 3.32 (s, 6H), 3.37 (s, 3H), 3.39 
(s, 3H), 3.48 (s, 3H), 3.65 (s, 3H), 3.68 (s, 3H), 3.70 (s, 3H), 3.80 (s, 3H), 3.84 (s, 3H), 3.85 (s, 
3H), 4.06 (dd, J = 10.7, 10.7 Hz, 1H, H6III), 4.61 (m, 2H, H5I and H6I), 5.02 (br d, J = 10.7 Hz, 
1H, H6I), 5.08 (d, J = 3.8 Hz, 1H), 5.13 (d, J = 3.8 Hz, 1H), 5.17 (d, J = 3.5 Hz, 1H, H1II), 5.18 (d, 
J = 4.1 Hz, 1H), 5.20 (d, J = 3.5 Hz, 1H), 5.22 (d, J = 3.5 Hz, 1H, H1I); 1H NMR (500 MHz, C6D6, 
1D-TOCSY, irradiation at H6I, 5.02 ppm): G 3.21 (dd, J = 9.6, 3.4 Hz, 1H, H2I), 3.58 (dd, J = 9.0, 
9.0 Hz, 1H, H4I), 3.83 (dd, J = 9.1, 9.1 Hz, 1H, H3I), 4.61 (m, 2H, H5I and H6I), 5.22 (d, J = 2.9 
Hz, 1H, H1I); 1H NMR (500 MHz, C6D6, 1D-TOCSY, irradiation at H1
II, 5.17 ppm): G 3.25 (dd, J 
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= 9.6, 2.7 Hz, 1H, H2II), 4.15 (dd, J = 9.3, 9.3 Hz, 1H, H3II), 4.26 (d, J = 9.4 Hz, 1H, H4II); 1H 
NMR (500 MHz, CDCl3, 1D-ROESY, irradiation at H1
I, 5.22 ppm): G 4.26 (d, J = 9.2 Hz, 1H, 
H4II); 13C NMR (125.7 MHz, CDCl3): G 20.98 (CH3), 57.77 (CH3), 57.83 (2 × CH3), 58.12 (CH3), 
58.20 (CH3), 58.39 (CH3), 58.92 (CH3), 58.99 (CH3), 59.09 (CH3), 59.17 (CH3), 61.30 (CH3), 61.56 
(CH3), 61.89 (CH3), 62.02 (CH3), 62.30 (CH3), 63.91 (CH2), 64.07 (CH2), 66.10 (CH), 69.20 (CH), 
70.75 (CH2), 70.86 (CH), 71.21 (CH2), 71.33 (CH2), 71.38 (CH), 71.48 (CH), 72.02 (CH2), 78.26 
(CH), 80.03 (CH), 80.60 (CH), 80.61 (CH), 80.83 (CH), 81.04 (CH), 81.06 (CH), 81.15 (CH), 
81.35 (CH), 81.42 (CH), 81.79 (2 × CH), 82.09 (CH), 82.11 (CH), 82.16 (CH), 82.35 (CH), 82.50 
(CH), 82.60 (CH), 97.39 (CH), 97.46 (CH), 99.09 (CH), 99.35 (CH), 100.05 (CH), 100.71 (CH), 
100.75 (C), 170.86 (C); 13C NMR (125.7 MHz, C6D6): G 20.78 (CH3), 57.24 (CH3), 57.67 (CH3), 
57.78 (2 × CH3), 58.15 (CH3), 58.25 (CH3), 58.84 (CH3), 58.97 (CH3), 59.01 (CH3), 59.10 (CH3), 
61.29 (CH3), 61.56 (CH3), 61.65 (CH3), 61.79 (CH3), 62.11 (CH3), 62.14 (CH3), 64.31 (CH2), 64.68 
(CH2), 66.70 (CH), 69.93 (CH), 71.74 (CH2), 71.79 (CH), 72.23 (CH), 72.25 (CH2), 72.50 (CH), 
72.72 (CH2), 73.00 (CH2), 79.05 (CH), 81.53 (CH), 81.57 (CH), 81.60 (CH), 81.63 (CH), 81.82 
(CH), 81.84 (CH), 82.04 (CH), 82.13 (2 × CH), 82.68 (CH), 82.72 (CH), 82.96 (CH), 83.00 (CH), 
83.06 (CH), 83.17 (CH), 83.31 (CH), 83.36 (CH), 98.06 (CH), 98.52 (CH), 99.08 (CH), 99.18 
(CH), 99.93 (CH), 100.88 (CH), 101.20 (C), 170.11 (C); MS (ESI+-TOF): m/z (%) 1259 [(M + 
Na)+, 100]; HRMS (ESI+-TOF): m/z [M + Na]+ calcd for C54H92NaO31 1259.5520; found 




(28). A solution of alcohol 26 (24 mg, 0.02 mmol) in dry pyridine (0.9 mL) containing Ac2O (0.3 
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mL) and DMAP (0.3 mg, 0.002 mmol) was stirred at room temperature for 14 h. The mixture was 
then poured into 10% aqueous HCl and extracted with CHCl3. The organic layer was washed with 
aqueous saturated NaHCO3, dried over Na2SO4 and concentrated under reduced pressure. The 
residue was then purified by silica gel (TLC Silica gel 60 F254, scraped from Merck Aluminum sheets) 
column chromatography (CHCl3±MeOH, 99.5:0.5) to give acetyl-trioxocane 28 (10 mg, 0.008 mmol, 
40%), as a colorless oil: [D]D +130.8 (c 0.98, CHCl3); IR (film): 2929, 1744, 1454, 1367, 1109, 
1046 cm±1; 1H NMR (500 MHz, CDCl3): G 2.07 (s, 3H), 3.179 (dd, J = 10.1, 3.5 Hz, 1H), 3.198 
(dd, J = 9.8, 3.5 Hz, 1H), 3.198 (dd, J = 9.8, 3.5 Hz, 1H), 3.257 (dd, J = 9.5, 3.2 Hz, 1H), 3.34 (s, 
3H), 3.37 (s, 3H), 3.381 (s, 3H), 3.384 (s, 3H), 3.47 (s, 3H), 3.476 (s, 3H), 3.489 (s, 3H), 3.494 (s, 
3H), 3.50 (s, 3H), 3.52 (s, 3H), 3.59 (s, 3H), 3.60 (s, 3H), 3.638 (s, 3H), 3.642 (s, 3H), 3.70 (s, 3H), 
3.73 (s, 3H), 3.93 (d, J = 9.5 Hz, 1H, H4VII), 4.39 (dd, J = 12.1, 4.3 Hz, 1H, H6III), 4.56 (dd, J = 
12.3, 1.9 Hz, 1H, H6III), 4.98 (d, J = 3.8 Hz, 2H), 5.04 (d, J = 3.5 Hz, 1H), 5.05 (d, J = 3.5 Hz, 2H), 
5.19 (d, J = 3.2 Hz, 1H, H1I); 1H NMR (500 MHz, CDCl3, 1D-TOCSY, irradiation at H6
III, 4.56 
ppm): G 3.14 (dd, J = 10.0, 3.3 Hz, 1H, H2III), 3.57 (dd, J = 9.1, 9.1 Hz, 1H, H4III), 3.69 (dd, J = 
9.4, 9.4 Hz, 1H, H3III), 3.77 (m, 1H, H5III), 4.40 (dd, J = 11.7, 3.9 Hz, 1H, H6III), 5.05 (d, J = 2.5 
Hz, 1H, H1III); 1H NMR (500 MHz, CDCl3, 1D-TOCSY, irradiation at H1
VI, 5.19 ppm): G 3.26 
(dd, J = 9.7, 3.2 Hz, 1H, H2VI), 3.72 (dd, J = 9.3, 9.3 Hz, 1H, H3VI), 3.94 (d, J = 9.4 Hz, 1H, H4VI); 
1H NMR (500 MHz, CDCl3, 1D-ROESY, irradiation at H4
VI, 3.93 ppm): G 5.04 (d, J = 3.2 Hz, 1H, 
H1V); 13C NMR (125.7 MHz, CDCl3): G 20.90 (CH3), 57.69 (CH3), 57.82 (CH3), 58.11 (2 × CH3), 
58.28 (CH3), 58.46 (CH3), 58.83 (CH3), 58.93 (CH3), 59.05 (CH3), 59.10 (CH3), 61.29 (CH3), 61.48 
(CH3), 61.59 (CH3), 61.85 (CH3), 62.08 (CH3), 62.27 (CH3), 63.69 (CH2), 63.85 (CH2), 66.21 (CH), 
69.89 (CH), 70.77 (CH2), 70.86 (CH), 70.98 (CH), 71.26 (CH), 71.35 (CH2), 71.56 (CH2), 71.96 
(CH2), 78.29 (CH), 79.87 (CH), 80.61 (CH), 80.76 (2 × CH), 81.04 (CH), 81.09 (CH), 81.17 (CH), 
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81.39 (CH), 81.51 (CH), 81.75 (CH), 81.94 (CH), 82.10 (CH), 82.17 (CH), 82.38 (CH), 82.49 
(CH), 82.71 (2 × CH), 97.32 (CH), 97.37 (CH), 99.50 (CH), 99.61 (CH), 99.78 (CH), 100.17 (CH), 
100.83 (C), 170.55 (C); MS (ESI+-TOF): m/z (%) 1259 [(M + Na)+, 100]; HRMS (ESI+-TOF): m/z 
[M + Na]+ calcd for C54H92NaO31 1259.5520; found 1259.5504. Anal. calcd for C54H92O31: C, 
52.42; H, 7.49. Found: C, 52.20; H, 7.65. 
Oxidative HAT of 2I-VII,3I-VII,6III-VII-nonadeca-O-methyl-E-cyclomaltoheptaose (29). A solution 
of alcohol 2917a (160 mg, 0.114 mmol) in dry CH2Cl2 (4.6 mL) containing DIB (110 mg, 0.34 
mmol) and I2 (49 mg, 0.19 mmol) was stirred under nitrogen at 28 
oC for 2.5 h while irradiated 
with two 80 W tungsten-filament lamps. The reaction mixture was then directly loaded onto a silica 
gel (TLC Silica gel 60 F254, scraped from Merck Aluminum sheets) column chromatography 
(hexanes±DFHWRQH ĺ WR JLYH cyclo-5VII,6I-anhydro-(5VIIR)-(2,3,6-tri-O-methyl-D-D-
xylo-hexos-5-ulopyranosyl)-ĺ-(1IR)-4II,6II-O-(2,3-di-O-methyl-D-glucopyranosylidene)-2,3-
di-O-methyl-D-D-glucopyranosyl->ĺ-2,3,6-tri-O-methyl-D-D-glucopyranosyl]4 (30) (8 mg, 
0.0057 mmol, 5%), ten-membered lactone 31 (17.1 mg, 0.012 mmol, 11%), and a mixture (54.1 
mg) of two alcohols 32 and 33 that was separated after acetylation as mentioned below. To a 
solution of this mixture in anhydrous pyridine (3 mL) were added Ac2O (1 mL) and DMAP (1 mg). 
After 14 h at room temperature, the solution was poured into ice-water and extracted with CH2Cl2. 
The organic phase was successively washed with aqueous solutions of HCl (10%) and saturated 
NaHCO3, dried over Na2SO4, and concentrated under reduced pressure. The residue (86.5 mg) was 
purified by silica gel (TLC Silica gel 60 F254, scraped from Merck Aluminum sheets) column 
chromatography (CHCl3±MeOH, 99:1) to give cyclo-5VII,6I-anhydro-(5VIIR)-(2,3,6-tri-O-methyl-D-
D-xylo-hexos-5-ulopyranosyl)-ĺ-2,3-di-O-methyl-D-D-glucopyranosyl-ĺ-6II-O-acetyl-
2,3-di-O-methyl-D-D-glucopyranosyl->ĺ-2,3,6-tri-O-methyl-D-D-glucopyranosyl]4 (34) (36 
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mg, 0.025 mmol, 22%) and the lactone 35 (16 mg, 0.013 mmol, 11%). Compound 30: colorless oil, 
[D]D +108.0 (c 0.45, CHCl3); IR (film): 2925, 1454, 1369, 1143, 1091, 1042 cm±1; 1H NMR (500 
MHz, CDCl3): G 3.06 (d, J = 9.5 Hz, 1H), 3.17 (dd, J = 9.5, 3.7 Hz, 1H), 3.19 (dd, J = 9.5, 3.2 Hz, 
1H), 3.209 (dd, J = 9.2, 4.1 Hz, 1H), 3.211 (dd, J = 9.5, 3.5 Hz, 1H), 3.22 (dd, J = 9.5, 3.8 Hz, 1H), 
3.27 (dd, J = 9.8, 3.8 Hz, 1H), 3.33 (s, 3H), 3.35 (s, 3H), 3.37 (s, 3H), 3.39 (s, 3H), 3.39 (s, 3H), 
3.47 (s, 3H), 3.47 (s, 3H), 3.50 (s, 3H), 3.51 (s, 3H), 3.55 (s, 3H), 3.56 (s, 3H), 3.59 (s, 9H), 3.64 
(s, 3H), 3.64 (s, 3H), 3.66 (s, 3H), 3.70 (s, 3H), 3.71 (s, 3H), 4.22 (dd, J = 10.4, 8.2 Hz, 1H), 5.04 
(d, J = 3.5 Hz, 1H), 5.07 (d, J = 3.2 Hz, 2H), 5.20 (d, J = 3.8 Hz, 1H), 5.23 (d, J = 4.4 Hz, 1H), 
5.34 (d, J = 4.1 Hz, 1H); 1H NMR (500 MHz, CDCl3, 1D-TOCSY, irradiation at H2
I, 3.06 ppm): 
G 3.40 (dd, J = 9.7, 9.7 Hz, 1H, H3I), 3.54 (dd, J = 9.3, 9.3 Hz, 1H, H4I), 3.75 (m, 2H, H6I and 
H5I), 3.90 (dd, J = 9.9, 9.9 Hz, 1H, H6I); 1H NMR (500 MHz, CDCl3, 1D-TOCSY, irradiation at 
H6II, 4.22 ppm): G 3.21 (dd, J = 9.6, 4.3 Hz, 1H, H2II), 3.57 (dd, J = 9.2, 9.2 Hz, 1H, H3II), 3.63 
(dd, J = 10.3, 6.8 Hz, 1H, H6II), 3.72 (dd, J = 10.0, 10.0 Hz, 1H, H4II), 4.00 (m, 1H, H5II), 5.23 (d, 
J = 4.0 Hz, 1H, H1II); 13C NMR (125.7 MHz, CDCl3): G 57.80 (CH3), 57.88 (CH3), 58.07 (CH3), 
58.22 (CH3), 58.91 (CH3), 59.02 (2 × CH3), 59.04 (CH3), 59.14 (CH3), 59.44 (CH3), 60.04 (CH3), 
60.57 (CH3), 60.70 (CH3), 60.96 (CH3), 61.07 (CH3), 61.18 (CH3), 61.67 (CH3), 61.70 (CH3), 61.84 
(CH2), 62.04 (CH3), 63.66 (CH), 64.36 (CH2), 67.62 (CH), 70.05 (CH), 70.07 (CH), 71.06 (CH), 
71.09 (CH2), 71.41 (CH), 71.49 (CH2), 71.83 (CH2), 71.84 (CH2), 71.93 (CH2), 74.10 (CH), 77.50 
(CH), 77.87 (CH), 78.37 (CH), 79.20 (CH), 80.18 (CH), 80.35 (CH), 81.02 (CH), 81.05 (CH), 
81.11 (CH), 81.37 (CH), 81.70 (CH), 81.80 (CH), 81.88 (CH), 81.92 (CH), 82.28 (CH), 82.34 
(CH), 82.45 (CH), 82.48 (CH), 82.76 (CH), 84.92 (CH), 97.04 (CH), 97.99 (CH), 98.61 (CH), 
98.83 (CH), 99.81 (CH), 100.31 (CH), 101.04 (C), 111.58 (C); MS (ESI+-TOF): m/z (%) 1419 [(M 
+ Na)+, 100]; HRMS (ESI+-TOF): m/z [M + Na]+ calcd for C61H104NaO35 1419.6256; found 
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1419.6281. Anal. calcd for C61H104O35: C, 52.43; H, 7.50. Found: C, 52.35; H, 7.73. Compound 
31: colorless oil, [D]D +121.8 (c 0.68, CHCl3); IR (film): 2929, 1755, 1745, 1454, 1367, 1161, 
1106, 1039 cm±1; 1H NMR (500 MHz, CDCl3): G 2.14 (s, 3H), 3.04 (dd, J = 9.8, 3.5 Hz, 1H), 3.16 
(dd, J = 9.8, 3.5 Hz, 1H), 3.16 (dd, J = 9.8, 3.5 Hz, 1H), 3.18 (dd, J = 9.8, 3.2 Hz, 1H), 3.19 (dd, J 
= 9.8, 3.5 Hz, 1H), 3.24 (dd, J = 9.5, 3.8 Hz, 1H), 3.35 (s, 3H), 3.361 (s, 3H), 3.365 (s, 3H), 3.37 
(s, 3H), 3.38 (s, 3H), 3.46 (s, 6H), 3.485 (s, 3H), 3.49 (s, 3H), 3.51 (s, 3H), 3.53 (s, 3H), 3.58 (s, 
3H), 3.59 (s, 3H), 3.61 (s, 3H), 3.62 (s, 3H), 3.63 (s, 3H), 3.66 (s, 3H), 3.69 (s, 3H), 3.73 (s, 3H), 
4.36 (ddd, J = 9.9, 9.9, 5.8 Hz, 1H), 4.58 (dd, J = 10.7, 5.7 Hz, 1H), 4.96 (d, J = 3.8 Hz, 1H), 5.00 
(d, J = 3.5 Hz, 1H), 5.09 (d, J = 3.8 Hz, 2H), 5.17 (d, J = 3.5 Hz, 1H), 5.26 (d, J = 3.8 Hz, 1H), 
6.30 (d, J = 1.9 Hz, 1H); 1H NMR (500 MHz, CDCl3, 1D-TOCSY, irradiation at H5
II, 4.36 ppm): 
G 3.05 (dd, J = 9.9, 3.4 Hz, 1H, H2II), 3.45 (dd, J = 8.8, 8.8 Hz, 1H, H3II), 3.55 (dd, J = 9.3, 9.3 Hz, 
1H, H4II), 3.81 (dd, J = 10.4, 10.4 Hz, 1H, H6II), 4.59 (dd, J = 10.8, 5.7 Hz, 1H, H6II), 5.00 (d, J = 
2.9 Hz, 1H, H1II); 1H NMR (500 MHz, CDCl3, 1D-TOCSY, irradiation at H1
I, 6.30 ppm): G 3.34 
(d, J = 9.0 Hz, 1H, H2I), 3.60 (m, 1H, H3I), 3.90 (d, J = 9.4 Hz, 1H, H4I); 1H NMR (500 MHz, 
CDCl3, 1D-ROESY, irradiation at H1
I, 6.30 ppm): G 3.34 (d, J = 7.1 Hz, 1H, H2I), 3.55 (dd, J = 
9.3, 9.3 Hz, 1H, H4II), 3.90 (d, J = 9.4 Hz, 1H, H4I); 13C NMR (125.7 MHz, CDCl3): G 21.43 (CH3), 
57.86 (CH3), 58.29 (2 × CH3), 58.39 (CH3), 58.40 (CH3), 58.83 (CH3), 58.94 (CH3), 58.99 (CH3), 
59.01 (CH3), 59.04 (2 × CH3), 60.97 (CH3), 61.25 (CH3), 61.50 (CH3), 61.69 (2 × CH3), 61.73 
(CH3), 62.20 (2 × CH3), 63.34 (CH), 65.84 (CH2), 70.17 (CH), 70.69 (CH), 70.82 (CH2), 70.93 (2 
× CH), 71.09 (CH), 71.12 (CH2), 71.14 (CH2), 71.35 (CH2), 71.66 (CH2), 78.64 (CH), 79.61 (CH), 
80.14 (CH), 80.52 (CH), 80.64 (CH), 80.89 (CH), 81.32 (2 × CH), 81.42 (CH), 81.58 (CH), 81.64 
(CH), 81.68 (CH), 81.81 (2 × CH), 81.84 (CH), 82.01 (CH), 82.05 (CH), 82.13 (CH), 82.27 (CH), 
83.42 (CH), 84.59 (CH), 94.21 (CH), 97.86 (CH), 98.70 (CH), 98.83 (CH), 99.11 (CH), 99.38 
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(CH), 99.98 (CH), 170.81 (C), 170.98 (C); MS (ESI+-TOF): m/z (%) 1449 [(M + Na)+, 100]; HRMS 
(ESI+-TOF): m/z [M + Na]+ calcd for C62H106NaO36 1449.6362; found 1449.6360. Anal. calcd for 
C62H106O36: C, 52.17; H, 7.48. Found: C, 51.91; H, 7.48. Compound 34: colorless oil, [D]D +105.2 
(c 0.94, CHCl3); IR (film): 2933, 1745, 1454, 1369, 1161, 1109, 1041 cm
±1; 1H NMR (500 MHz, 
CDCl3): G 2.08 (s, 3H), 3.13 (dd, J = 9.5, 3.5 Hz, 1H), 3.28 (dd, J = 9.6, 3.6 Hz, 1H), 3.368 (s, 3H), 
3.373 (s, 3H), 3.38 (s, 6H), 3.40 (s, 3H), 3.46 (s, 6H), 3.50 (s, 9H), 3.51 (s, 6H), 3.58 (s, 3H), 3.61 
(s, 3H), 3.62 (s, 3H), 3.62 (s, 3H), 3.64 (s, 3H), 3.65 (s, 3H), 3.69 (s, 3H), 4.29 (dd, J = 12.3, 3.8 
Hz, 1H), 4.49 (dd, J = 12.0, 1.9 Hz, 1H), 4.92 (d, J = 3.5 Hz, 1H), 5.07 (d, J = 3.5 Hz, 1H), 5.074 
(d, J = 3.8 Hz, 1H), 5.09 (d, J = 3.5 Hz, 1H), 5.13 (d, J = 3.5 Hz, 1H), 5.20 (d, J = 3.8 Hz, 1H), 
5.23 (d, J = 3.8 Hz, 1H); 1H NMR (500 MHz, CDCl3, 1D-TOCSY, irradiation at H1
I, 4.92 ppm): 
G 3.14 (dd, J = 9.0, 2.8 Hz, 1H, H2I), 3.53 (dd, J = 8.7, 8.7 Hz, 1H, H4I), 3.59 (dd, J = 9.5, 9.5 Hz, 
1H, H3I); 1H NMR (500 MHz, CDCl3, 1D-TOCSY, irradiation at H6
II, 4.29 ppm): G 3.19 (dd, J = 
9.7, 3.9 Hz, 1H, H2II), 3.40 (dd, J = 9.2, 9.2 Hz, 1H, H3II), 3.57 (dd, J = 9.7, 9.7 Hz, 1H, H4II), 4.49 
(br d, J = 11.6 Hz, 1H, H6II), 5.08 (d, J = 3.3 Hz, 1H, H1II); 1H NMR (500 MHz, CDCl3, 1D-
ROESY, irradiation at H1I, 4.92 ppm): G 3.14 (dd, J = 9.4, 3.2 Hz, 1H, H2I), 3.56 (dd, J = 9.4, 9.4 
Hz, 1H, H4II); 13C NMR (125.7 MHz, CDCl3): G 20.84 (CH3), 57.86 (CH3), 57.89 (CH3), 58.09 
(CH3), 58.42 (CH3), 58.45 (CH3), 58.72 (CH3), 58.88 (CH3), 58.97 (CH3), 59.00 (2 × CH3), 59.07 
(CH3), 59.11 (CH3), 60.81 (CH3), 61.02 (CH3), 61.35 (CH3), 61.55 (CH3), 61.66 (CH3), 61.85 
(CH3), 62.16 (CH3), 63.36 (CH2), 64.58 (CH2), 67.04 (CH), 69.46 (CH), 70.67 (CH), 70.89 (CH), 
70.96 (CH), 70.96 (CH2), 70.99 (CH), 71.03 (CH2), 71.36 (CH2), 71.74 (CH2), 71.83 (CH2), 77.62 
(CH), 78.85 (CH), 79.05 (CH), 80.19 (CH), 80.29 (CH), 80.51 (CH), 80.82 (CH), 81.13 (CH), 
81.21 (CH), 81.31 (CH), 81.42 (CH), 81.46 (CH), 81.51 (CH), 81.79 (2 × CH), 81.80 (CH), 81.83 
(CH), 81.98 (CH), 82.27 (CH), 82.35 (CH), 82.67 (CH), 97.02 (CH), 97.81 (CH), 98.95 (CH), 
60 
 
99.02 (CH), 99.03 (CH), 99.39 (CH), 99.49 (CH), 101.12 (C), 170.50 (C); MS (ESI+-TOF): m/z 
(%) 1463 [(M + Na)+, 100]; HRMS (ESI+-TOF): m/z [M + Na]+ calcd for C63H108NaO36 1463.6518; 
found 1463.6530. Anal. calcd for C63H108O36: C, 52.49; H, 7.55. Found: C, 52.58; H, 7.63. 
Compound 35: colorless oil, [D]D +120.3 (c 0.64, CHCl3); IR (film): 2929, 1745, 1454, 1369, 1159, 
1107, 1041 cm±1; 1H NMR (500 MHz, CDCl3): G 2.10 (s, 3H), 3.18 (dd, J = 9.8, 3.8 Hz, 4H), 3.25 
(dd, J = 9.8, 3.8 Hz, 1H), 3.35 (s, 3H), 3.37 (s, 3H), 3.38 (s, 3H), 3.385 (s, 3H), 3.389 (s, 3H), 3.45 
(dd, J = 9.8, 2.8 Hz, 1H), 3.49 (s, 3H), 3.49 (s, 9H), 3.51 (s, 3H), 3.54 (s, 3H), 3.60 (s, 3H), 3.62 
(s, 9H), 3.63 (s, 3H), 3.64 (s, 3H), 3.67 (s, 6H), 3.95 (dd, J = 9.5, 9.5 Hz, 1H), 3.99 (ddd, J = 9.8, 
3.9, 1.7 Hz, 1H), 4.17 (d, J = 8.5 Hz, 1H), 4.21 (ddd, J = 10.1, 1.9, 1.9 Hz, 1H), 4.29 (dd, J = 12.5, 
3.9 Hz, 1H), 4.45 (dd, J = 12.3, 1.9 Hz, 1H), 5.11 (d, J = 3.5 Hz, 1H), 5.12 (d, J = 3.8 Hz, 1H), 
5.13 (d, J = 3.8 Hz, 1H), 5.17 (d, J = 3.8 Hz, 1H), 5.23 (d, J = 3.8 Hz, 1H), 5.25 (d, J = 3.2 Hz, 
1H), 5.56 (d, J = 3.2 Hz, 1H); 1H NMR (500 MHz, CDCl3, 1D-TOCSY, irradiation at H1
I, 5.56 
ppm): G 3.45 (dd, J = 9.6, 2.9 Hz, 1H, H2I), 3.96 (dd, J = 9.0, 9.0 Hz, 1H, H3I), 4.18 (d, J = 8.8 Hz, 
1H, H4I); 1H NMR (500 MHz, CDCl3, 1D-TOCSY, irradiation at H6
II, 4.45 ppm): G 3.19 (dd, J = 
9.7, 3.4 Hz, 1H, H2II), 3.57 (dd, J = 9.3, 9.3 Hz, 1H, H3II), 3.71 (dd, J = 9.5, 9.5 Hz, 1H, H4II), 3.99 
(m, 1H, H5II), 4.30 (dd, J = 12.4, 3.8 Hz, 1H, H6II), 5.12 (d, J = 3.0 Hz, 1H, H1II); 13C NMR (125.7 
MHz, CDCl3): G 20.85 (CH3), 58.16 (CH3), 58.22 (CH3), 58.28 (CH3), 58.42 (CH3), 58.62 (CH3), 
58.79 (CH3), 58.97 (2 × CH3), 59.02 (CH3), 59.06 (CH3), 59.13 (CH3), 59.18 (CH3), 60.53 (CH3), 
61.22 (CH3), 61.23 (CH3), 61.27 (CH3), 61.43 (CH3), 61.47 (2 × CH3), 62.87 (CH2), 68.67 (CH), 
70.77 (CH2), 70.77 (CH), 70.88 (CH), 70.90 (CH), 70.92 (CH), 70.99 (CH2), 71.12 (CH), 71.14 
(CH2), 71.21 (CH2), 71.41 (CH2), 78.45 (CH), 78.63 (CH), 78.80 (CH), 79.29 (CH), 79.98 (CH), 
80.03 (CH), 80.19 (CH), 80.39 (CH), 80.77 (CH), 81.31 (CH), 81.46 (CH), 81.71 (3 × CH), 81.80 
(CH), 81.97 (CH), 82.14 (CH), 82.19 (CH), 82.27 (2 × CH), 82.38 (CH), 97.91 (CH), 98.11 (CH), 
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98.64 (CH), 99.02 (CH), 99.11 (CH), 99.22 (CH), 99.60 (CH), 168.56 (C), 170.41 (C); MS (ESI+-
TOF): m/z (%) 1449 [(M + Na)+, 100]; HRMS (ESI+-TOF): m/z [M + Na]+ calcd for C62H106NaO36 
1449.6362; found 1449.6410. Anal. calcd for C62H106O36: C, 52.17; H, 7.48. Found: C, 52.46; H, 
7.40. 
Oxidative HAT of 2I-VI,3I-VI,6III-VI-hexadeca-O-methyl-D-cyclomaltohexaose (36). A solution of 
alcohol 3635 (150 mg, 0.125 mmol) in dry CH2Cl2 (5 mL) containing DIB (88 mg, 0.27 mmol) and 
I2 (32 mg, 0.125 mmol) was stirred under nitrogen at 28 oC for 1.5 h while irradiated with two 80 
W tungsten-filament lamps. The reaction mixture was then directly loaded onto a silica gel (TLC 
Silica gel 60 F254, scraped from Merck Aluminum sheets) column chromatography (hexanes±acetone, 
ĺ WR JLYH WKH WHQ-membered lactone 37 (23 mg, 0.019 mmol, 16%), cyclo-5VI,6I-
anhydro-(5VIR)-(2,3,6-tri-O-methyl-D-D-xylo-hexos-5-ulopyranosyl)->ĺ-2,3-di-O-methyl-D-
D-glucopyranosyl]2->ĺ-2,3,6-tri-O-methyl-D-D-glucopyranosyl]3 (38) (37 mg, 0.031 mmol, 
25%), and the lactone-alcohol 39 (14.6 mg, 0.012 mmol, 10%). Compound 37: colorless oil, [D]D 
+131.7 (c 1.31, CHCl3); IR (film): 2929, 1760, 1745, 1454, 1367, 1107, 1046 cm±1; 1H NMR (500 
MHz, CDCl3): G 2.12 (s, 3H), 3.09 (dd, J = 9.9, 3.3 Hz, 1H), 3.12 (dd, J = 10.1, 3.2 Hz, 1H), 3.17 
(dd, J = 9.8, 3.5 Hz, 2H), 3.20 (dd, J = 10.1, 3.5 Hz, 1H), 3.36 (s, 3H), 3.36 (s, 3H), 3.38 (s, 3H), 
3.38 (s, 3H), 3.44 (s, 3H), 3.48 (s, 3H), 3.49 (s, 3H), 3.50 (s, 3H), 3.52 (s, 6H), 3.55 (s, 3H), 3.59 
(s, 3H), 3.60 (s, 3H), 3.60 (s, 3H), 3.70 (s, 3H), 3.74 (s, 3H), 3.87 (dd, J = 11.0, 3.8 Hz, 1H), 3.92 
(dd, J = 10.7, 10.7 Hz, 1H), 3.94 (dd, J = 10.4, 3.2 Hz, 1H), 4.09 (d, J = 5.7 Hz, 1H), 4.33 (ddd, J 
= 10.1, 4.1, 1.6 Hz, 1H), 4.48 (dd, J = 10.7, 5.4 Hz, 1H), 4.61 (ddd, J = 10.1, 10.1, 5.4 Hz, 1H), 
4.95 (d, J = 3.5 Hz, 2H), 5.02 (d, J = 3.5 Hz, 1H), 5.07 (d, J = 3.2 Hz, 2H), 6.37 (d, J = 1.3 Hz, 
1H); 1H NMR (500 MHz, CDCl3, 1D-TOCSY, irradiation at H1I, 6.37 ppm): G 3.59 (d, J = 7.7 Hz, 
1H, H2I), 3.73 (m, 1H, H3I), 4.09 (d, J = 5.8 Hz, 1H, H4I); 1H NMR (500 MHz, CDCl3, 1D-
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TOCSY, irradiation at H5II, 4.61 ppm): G 3.08 (dd, J = 9.9, 3.3 Hz, 1H, H2II), 3.44 (dd, J = 9.1, 9.1 
Hz, 1H, H3II), 3.59 (dd, J = 9.6, 9.6 Hz, 1H, H4II), 3.91 (dd, J = 10.6, 10.6 Hz, 1H, H6II), 4.48 (dd, 
J = 10.8, 5.3 Hz, 1H, H6II), 4.94 (d, J = 2.5 Hz, 1H, H1II); 1H NMR (500 MHz, CDCl3, 1D-TOCSY, 
irradiation at H5VI, 4.33 ppm): G 3.19 (dd, J = 9.9, 2.9 Hz, 1H, H2VI), 3.49 (dd, J = 9.6, 9.6 Hz, 1H, 
H4VI), 3.68 (dd, J = 9.6, 9.6 Hz, 1H, H3VI), 4.94 (d, J = 2.7 Hz, 1H, H1VI); 1H NMR (500 MHz, 
CDCl3, 1D-ROESY, irradiation at H1I, 6.37 ppm): G 3.59 (dd, J = 9.3, 9.3 Hz, 1H, H4II), 4.09 (d, 
J = 5.5 Hz, 1H, H4I); 1H NMR (500 MHz, CDCl3, 1D-ROESY, irradiation at H4I, 4.09 ppm): G 
4.95 (d, J = 3.5 Hz, 1H, H1VI); 13C NMR (125.7 MHz, CDCl3): G 21.48 (CH3), 57.71 (CH3), 57.76 
(CH3), 58.02 (CH3), 58.25 (CH3), 58.33 (CH3), 58.56 (CH3), 58.89 (CH3), 58.91 (CH3), 58.99 
(CH3), 60.13 (CH3), 60.68 (CH3), 61.30 (CH3), 61.40 (CH3), 61.66 (CH3), 61.99 (CH3), 62.10 
(CH3), 62.60 (CH), 66.24 (CH2), 70.79 (CH), 70.82 (CH), 71.07 (CH2), 71.17 (CH), 71.35 (2 × 
CH2), 71.39 (CH), 71.51 (CH2), 79.60 (CH), 81.04 (CH), 81.11 (2 × CH), 81.14 (CH), 81.26 (CH), 
81.40 (CH), 81.43 (CH), 81.52 (2 × CH), 81.65 (CH), 81.83 (2 × CH), 81.90 (CH), 81.96 (2 × CH), 
82.33 (CH), 83.00 (CH), 94.66 (CH), 98.56 (CH), 98.90 (CH), 99.53 (CH), 99.64 (CH), 99.80 
(CH), 170.02 (C), 170.23 (C); MS (ESI+-TOF): m/z (%) 1245 [(M + Na)+, 100]; HRMS (ESI+-
TOF): m/z [M + Na]+ calcd for C53H90NaO31 1245.5364; found 1245.5369. Anal. calcd for 
C53H90O31: C, 52.04; H, 7.42. Found: C, 52.15; H, 7.33. Compound 38: colorless oil, [D]D +134.3 
(c 1.32, CHCl3); IR (film): 3475, 2929, 1454, 1367, 1139, 1107, 1046 cm±1; 1H NMR (500 MHz, 
CDCl3): G 3.10±3.17 (m, 4H), 3.19 (dd, J = 9.9, 3.3 Hz, 1H), 3.25 (dd, J = 9.8, 3.2 Hz, 1H), 3.35 
(s, 3H), 3.36 (s, 3H), 3.369 (s, 3H), 3.372 (s, 3H), 3.46 (s, 6H), 3.48 (s, 3H), 3.49 (s, 3H), 3.50 (s, 
3H), 3.51 (s, 3H), 3.58 (s, 3H), 3.60 (s, 3H), 3.62 (s, 3H), 3.64 (s, 3H), 3.70 (s, 3H), 3.73 (s, 3H), 
5.00 (d, J = 3.8 Hz, 1H), 5.01 (d, J = 3.8 Hz, 1H), 5.025 (d, J = 3.8 Hz, 1H), 5.033 (d, J = 4.1 Hz, 
1H), 5.06 (d, J = 3.2 Hz, 1H), 5.18 (d, J = 3.5 Hz, 1H); 13C NMR (125.7 MHz, CDCl3): G 57.66 
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(CH3), 57.82 (CH3), 57.94 (2 × CH3), 58.34 (CH3), 58.51 (CH3), 58.74 (CH3), 58.79 (CH3), 59.07 
(CH3), 59.14 (CH3), 61.26 (CH3), 61.44 (CH3), 61.52 (CH3), 61.86 (CH2), 61.93 (CH3), 61.98 
(CH3), 62.24 (CH3), 63.80 (CH2), 66.28 (CH), 70.90 (CH), 70.93 (CH), 71.24 (CH2), 71.57 (CH), 
71.80 (CH2), 71.82 (CH2), 71.94 (CH2), 72.04 (CH), 78.29 (CH), 80.35 (CH), 80.56 (CH), 80.74 
(CH), 80.96 (CH), 81.03 (CH), 81.07 (CH), 81.26 (CH), 81.40 (2 × CH), 81.72 (CH), 81.96 (CH), 
82.01 (2 × CH), 82.23 (CH), 82.31 (CH), 82.59 (CH), 82.72 (CH), 97.35 (CH), 97.79 (CH), 98.77 
(CH), 99.62 (CH), 99.90 (CH), 100.07 (CH), 100.81 (C); MS (ESI+-TOF): m/z (%) 1217 [(M + 
Na)+, 100]; HRMS (ESI+-TOF): m/z [M + Na]+ calcd for C52H90NaO30 1217.5415; found 
1217.5419. Anal. calcd for C52H90O30: C, 52.25; H, 7.59. Found: C, 52.43; H, 7.61. Compound 39: 
colorless oil, [D]D +111.4 (c 0.96, CHCl3); IR (film): 3468, 2929, 1757, 1454, 1367, 1137, 1109, 
1044 cm±1; 1H NMR (500 MHz, CDCl3): G 3.13±3.20 (m, 3H), 3.23 (dd, J = 9.8, 3.5 Hz, 1H), 3.38 
(s, 3H), 3.385 (s, 6H), 3.39 (s, 3H), 3.48 (s, 6H), 3.49 (s, 3H), 3.50 (s, 3H), 3.51 (s, 3H), 3.58 (s, 
3H), 3.63 (s, 6H), 3.64 (s, 3H), 3.65 (s, 3H), 3.66 (s, 3H), 3.69 (s, 3H), 3.87 (dd, J = 8.5, 8.5 Hz, 
1H), 4.03 (d, J = 8.5 Hz, 1H), 4.08±4.15 (m, 1H), 4.24 (ddd, J = 10.1, 2.8, 1.6 Hz, 1H), 5.06 (d, J 
= 3.5 Hz, 2H), 5.065 (d, J = 3.8 Hz, 1H), 5.12 (d, J = 3.5 Hz, 1H), 5.16 (d, J = 3.5 Hz, 1H), 5.47 
(d, J = 2.8 Hz, 1H); 1H NMR (500 MHz, CDCl3, 1D-TOCSY, irradiation at H1I, 5.47 ppm): G 3.45 
(dd, J = 10.0, 2.7 Hz, 1H, H2I), 3.88 (dd, J = 9.3, 9.3 Hz, 1H, H3I), 4.03 (d, J = 8.7 Hz, 1H, H4I); 
1H NMR (500 MHz, CDCl3, 1D-TOCSY, irradiation at H5VI, 4.24 ppm): G 3.24 (dd, J = 9.7, 3.6 
Hz, 1H, H2VI), 3.60 (dd, J = 10.0, 9.4 Hz, 1H, H4VI), 3.69 (dd, J = 9.4, 9.4 Hz, 1H, H3VI), 3.89 (dd, 
J = 10.7, 3.1 Hz, 1H, H6VI), 5.17 (d, J = 2.9 Hz, 1H, H1VI); 1H NMR (500 MHz, CDCl3, 1D-
ROESY, irradiation at H4I, 4.03 ppm): G 5.16 (d, J = 3.4 Hz, 1H, H1VI); 13C NMR (125.7 MHz, 
CDCl3): G 57.91 (4 × CH3), 58.35 (CH3), 58.91 (2 × CH3), 58.98 (2 × CH3), 59.14 (CH3), 61.24 
(CH3), 61.56 (CH3), 61.56 (CH2), 61.62 (CH3), 61.65 (CH3), 61.75 (2 × CH3), 71.08 (2 × CH), 
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71.08 (CH2), 71.13 (CH), 71.21 (CH2), 71.25 (CH2), 71.34 (CH2), 71.36 (CH), 71.65 (CH), 80.02 
(CH), 80.13 (CH), 80.29 (CH), 81.20 (CH), 81.23 (CH), 81.26 (CH), 81.34 (CH), 81.51 (CH), 
81.78 (CH), 81.84 (2 × CH), 81.89 (CH), 81.97 (CH), 82.01 (CH), 82.11 (2 × CH), 82.16 (CH), 
82.32 (CH), 99.26 (CH), 99.39 (CH), 99.68 (CH), 99.74 (CH), 100.34 (CH), 100.37 (CH), 169.42 
(C); MS (ESI+-TOF): m/z (%) 1203 [(M + Na)+, 100] HRMS (ESI+-TOF): m/z [M + Na]+ calcd for 
C51H88NaO30 1203.5258; found 1203.5254. Anal. calcd for C51H88O30: C, 51.86; H, 7.51. Found: 
C, 51.74; H, 7.40. 
Methyl 6-O-tert-Butyldiphenylsilyl-2,3,4-tri-O-methyl-D-D-glucopyranosyl-ĺ-6-O-tert-
butyldiphenylsilyl-2,3-di-O-methyl-E-D-glucopyranoside (40E) and Methyl 6-O-tert-
Butyldiphenylsilyl-2,3,4-tri-O-methyl-D-D-glucopyranosyl-ĺ-6-O-tert-butyldiphenylsilyl-
2,3-di-O-methyl-D-D-glucopyranoside (40D). To a solution of dry D-(+)-maltose (5 g, 14.6 mmol), 
imidazole (8.9 g, 131.6 mmol), and DMAP (8.9 g, 73.1 mmol) in dry DMF (75 mL) was added 
TBDPSCl (22.8 mL, 87.7 mmol) at 0 oC. The mixture was stirred at room temperature for 20 h, 
poured into water, and extracted with CH2Cl2. The organic phase was washed with HCl (10%), 
saturated aqueous NaHCO3, and concentrated under reduced pressure to give a residue that was 
dried over P2O5 in a high vacuum desiccator for 24 h and used in the subsequent reaction as a 
mixture without further purification. NaH (60%, 7 g, 175 mmol) was added in portions to a solution 
of the crude residue (32 g) in dry DMF I mL) cooled to 0 oC and the mixture stirred at this 
temperature for 1 h. MeI (13.7 mL, 219.3 mmol) was then added dropwise and the stirring 
continued for 3 h at room temperature. The excess of NaH was destroyed with MeOH and the 
mixture poured into water, extracted with CH2Cl2 and concentrated under reduced pressure. The 
residue was purified by silica gel column chromatography (hexanes±(W2$FĺDQGRQO\
the disilylated anomeric isomers 40E (4.3 g, 4.76 mmol, 33%) and 40D (1.6 g, 1.78 mmol, 12%) 
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were studied. Compound 40E: Rf = 0.49 (n-hexane±EtOAc, 7:3), colorless oil, [D]D +44.5 (c 1.19, 
CHCl3); IR (film): 2933, 1148, 1104 cm
±1; 1H NMR (500 MHz, CDCl3): G 0.94 (s, 9H), 1.00 (s, 
9H), 3.04 (dd, J = 9.1, 7.9 Hz, 1H), 3.12 (dd, J = 9.6, 3.9 Hz, 1H), 3.31 (m, 1H), 3.39 (m, 3H), 3.45 
(dd, J = 8.8, 8.8 Hz, 1H), 3.48 (m, 2H), 3.53 (s, 3H), 3.53 (s, 3H), 3.57 (s, 3H), 3.59 (s, 3H), 3.60 
(s, 3H), 3.64 (s, 3H), 3.66 (dd, J = 9.8, 8.8 Hz, 1H), 3.74 (dd, J = 11.0, 5.7 Hz, 1H), 3.85 (dd, J = 
11.0, 2.2 Hz, 1H), 4.17 (d, J = 7.6 Hz, 1H), 5.55 (d, J = 4.1 Hz, 1H), 7.15±7.66 (m, 20H); 1H NMR 
(500 MHz, CDCl3, 1D-TOCSY, irradiation at H1
I, 4.17 ppm): G 3.04 (dd, J = 8.8, 8.1 Hz, 1H, H2I), 
3.41 (m, 1H, H5I), 4.45 (dd, J = 8.9, 8.9 Hz, 1H, H3I), 3.66 (dd, J = 9.3, 9.3 Hz, 1H, H4I), 3.74 (dd, 
J = 11.2, 5.9 Hz, 1H, H6aI), 3.84 (dd, J = 10.9, 2.3 Hz, 1H, H6bI); 1H NMR (500 MHz, CDCl3, 
1D-TOCSY, irradiation at H1II, 5.55 ppm): G 3.11 (dd, J = 9.3, 3.4 Hz, 1H, H2II), 3.31 (m, 1H, 
H5II), 3.37 (m, 2H, H3II and H4II), 3.46 (br d, J = 11.1 Hz, 1H, H6aII), 3.52 (br d, J = 11.3 Hz, 1H, 
H6bII); 13C NMR (125.7 MHz, CDCl3): G 19.23 (C), 19.31 (C), 26.79 (3 × CH3), 26.81 (3 × CH3), 
56.67 (CH3), 59.15 (CH3), 59.58 (CH3), 60.16 (CH3), 60.18 (CH3), 60.71 (CH3), 62.14 (CH2), 63.61 
(CH2), 71.89 (CH), 72.06 (CH), 75.11 (CH), 78.84 (CH), 81.90 (CH), 83.38 (CH), 83.77 (CH), 
86.41 (CH), 96.12 (CH), 104.04 (CH), 127.43 (2 × CH), 127.47 (2 × CH), 127.49 (2 × CH), 127.54 
(2 × CH), 129.36 (CH), 129.43 (CH), 129.47 (2 × CH), 133.27 (C), 133.34 (C), 133.72 (C), 133.86 
(C), 135.38 (2 × CH), 135.56 (2 × CH), 135.77 (4 × CH); MS (ESI+-TOF): m/z (%) 925 [(M + 
Na)+, 100]; HRMS (ESI+-TOF): m/z [M + Na]+ calcd for C50H70NaO11Si2 925.4354; found 
925.4366. Anal. calcd for C50H70O11Si2: C, 66.49; H, 7.81. Found: C, 66.75; H, 7.93. Compound 
40D: Rf = 0.42 (n-hexane±EtOAc, 7:3), colorless oil, [D]D +86.3 (c 1.067, CHCl3); IR (film): 2933, 
1156, 1104, 1029 cm±1; 1H NMR (500 MHz, CDCl3): G 0.94 (s, 9H), 0.99 (s, 9H), 3.11 (dd, J = 
9.8, 4.1 Hz, 1H), 3.17 (dd, J = 9.6, 3.6 Hz, 1H), 3.36 (s, 3H), 3.51 (s, 6H), 3.56 (s, 3H), 3.60 (s, 
3H), 3.63 (s, 3H), 4.78 (d, J = 3.5 Hz, 1H), 5.55 (d, J = 4.1 Hz, 1H), 7.16±7.66 (m, 20H); 13C NMR 
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(125.7 MHz, CDCl3): G 19.24 (C), 19.30 (C), 26.81 (6 × CH3), 54.59 (CH3), 58.69 (CH3), 59.52 
(CH3), 60.00 (CH3), 60.14 (CH3), 60.70 (CH3), 62.22 (CH2), 63.63 (CH2), 70.66 (CH), 71.92 (CH), 
72.48 (CH), 78.86 (CH), 81.93 (CH), 82.43 (CH), 83.37 (CH), 83.52 (CH), 96.27 (CH), 96.50 
(CH), 127.42 (2 × CH), 127.44 (2 × CH), 127.46 (2 × CH), 127.53 (2 × CH), 129.35 (CH), 129.39 
(CH), 129.43 (CH), 129.45 (CH), 133.38 (C), 133.41 (C), 133.77 (C), 133.88 (C), 135.48 (2 × CH), 
135.60 (2 × CH), 135.72 (2 × CH), 135.80 (2 × CH); MS (ESI+-TOF): m/z (%) 925 [(M + Na)+, 
100]; HRMS (ESI+-TOF): m/z [M + Na]+ calcd for C50H70NaO11Si2 925.4354; found 925.4358. 
Anal. calcd for C50H70O11Si2: C, 66.49; H, 7.81. Found: C, 66.10; H, 7.92. 
Methyl 2,3,4-Tri-O-methyl-D-D-glucopyranosyl-ĺ-2,3-di-O-methyl-E-D-glucopyranoside 
(41). To a solution of 40E (2 g, 2.2 mmol) in THF (50 mL) was added TBAF (1 M in THF, 6.6 mL, 
6.6 mmol) and the mixture stirred at room temperature for 7 h. The THF was the removed under 
vacuum and the resulting oil purified by column chromatography (hexanes±(W2$Fĺ(W2$F
to give the compound 41 (675 mg, 1.58 mmol, 72%) as a colorless oil; [D]D +74.1 (c 1.077, CHCl3); 
IR (film): 3460, 2936, 1144, 1081, 1029 cm±1; 1H NMR (500 MHz, CDCl3): G 3.00 (dd, J = 9.8, 
8.8 Hz, 1H), 3.03 (dd, J = 9.1, 7.9 Hz, 1H), 3.15 (dd, J = 9.8, 4.1 Hz, 1H), 3.35 (ddd, J = 9.8, 2.8, 
2.8 Hz, 1H), 3.43 (dd, J = 10.4, 9.1 Hz, 1H), 3.43 (dd, J = 8.8, 8.8 Hz, 1H), 3.52 (s, 3H), 3.53 (s, 
3H), 3.55 (s, 3H), 3.57 (s, 3H), 3.58 (s, 3H), 3.60 (s, 3H), 3.63 (s, 3H), 3.65 (dd, J = 11.4, 6.0 Hz, 
1H), 3.81 (dd, J = 12.3, 2.8 Hz, 1H), 3.85 (dd, J = 12.3, 3.2 Hz, 1H), 3.85 (dd, J = 11.7, 2.2 Hz, 
1H), 3.88 (dd, J = 9.5, 9.5 Hz, 1H), 4.19 (d, J = 7.9 Hz, 1H), 5.61 (d, J = 4.1 Hz, 1H); 13C NMR 
(125.7 MHz, CDCl3): G 57.0 (CH3), 59.9 (CH3), 60.1 (CH3), 60.2 (CH3), 60.6 (CH3), 60.8 (CH3), 
60.9 (CH2), 61.9 (CH2), 71.3 (CH), 72.2 (CH), 74.2 (CH), 80.5 (CH), 81.8 (CH), 83.5 (CH), 84.3 
(CH), 86.5 (CH), 96.5 (CH), 104.3 (CH); MS (ESI+-TOF): m/z (%) 449 [(M + Na)+, 100]; HRMS 
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(ESI+-TOF): m/z [M + Na]+ calcd for C18H34NaO11 449.1999; found 449.1994. Anal. calcd for 
C18H34O11: C, 50.70; H, 8.04. Found: C, 50.35; H, 8.24. 
Oxidative HAT of Methyl 2,3,4-Tri-O-methyl-D-D-glucopyranosyl-ĺ-2,3-di-O-methyl-E-D-
glucopyranoside (41). A solution of alcohol 41 (100 mg, 0.235 mmol) in dry CH2Cl2 (9.4 mL) 
containing DIB (166.5 mg, 0.516 mmol) and I2 (60 mg, 0.235 mmol) was stirred under nitrogen at 
32 oC for 3 h while irradiated with two 80 W tungsten-filament lamps. The reaction mixture was 
then directly loaded onto a silica gel (TLC Silica gel 60 F254, scraped from Merck Aluminum sheets) 
column chromatography (hexanes±DFHWRQHĺWRJLYHWKHWHQ-membered lactone 42 (11 
mg, 0.024 mmol, 9%) and the acetyl-derivative 43 (11 mg, 0.023 mmol, 10%). Compound 42: 
colorless oil, [D]D ±24.2 (c 0.520, CHCl3); IR (film): 2938, 1746, 1455, 1372, 1126, 1095 cm±1; 1H 
NMR (500 MHz, CDCl3): G 2.13 (s, 3H), 2.89 (dd, J = 9.3, 7.7 Hz, 1H, H2II), 3.15 (dd, J = 8.8, 8.8 
Hz, 1H, H3II), 3.31 (dd, J = 7.7, 2.0 Hz, 1H, H2I), 3.45 (s, 3H), 3.49 (s, 3H), 3.53 (s, 3H), 3.56 (dd, 
J = 8.4, 8.4 Hz, 1H, H3I), 3.59 (s, 3H), 3.60 (s, 3H), 3.61 (s, 3H), 3.62 (dd, J = 9.1, 9.1 Hz, 1H, 
H4II), 3.75 (d, J = 8.8 Hz, 1H, H4I), 3.80 (ddd, J = 9.8, 9.8, 5.4 Hz, 1H, H5II), 4.12 (d, J = 7.9 Hz, 
1H, H1II), 4.18 (dd, J = 11.4, 9.8 Hz, 1H, H6II), 4.59 (dd, J = 11.2, 5.2 Hz, 1H, H6II), 6.23 (d, J = 
2.2 Hz, 1H, H1I); 1H NMR (500 MHz, CDCl3, 1D-TOCSY, irradiation at H1I, 6.23 ppm): G 3.31 
(dd, J = 7.8, 1.9 Hz, 1H, H2I), 3.56 (dd, J = 8.4, 8.4 Hz, 1H, H3I), 3.76 (d, J = 8.7 Hz, 1H, H4I); 1H 
NMR (500 MHz, CDCl3, 1D-TOCSY, irradiation at H2II, 2.89 ppm): G 3.15 (dd, J = 8.9, 8.9 Hz, 
1H, H3II), 3.63 (dd, J = 9.2, 9.2 Hz, 1H, H4II), 3.81 (ddd, J = 9.3, 9.3, 5.4 Hz, 1H, H5II), 4.13 (d, J 
= 7.8 Hz, 1H, H1II), 4.19 (dd, J = 10.6, 10.6 Hz, 1H, H6II), 4.60 (dd, J = 11.0, 5.2 Hz, 1H, H6II); 
13C NMR (125.7 MHz, CDCl3): G 21.34 (CH3), 57.08 (CH3), 59.00 (CH3), 60.43 (CH3), 61.64 (2 
× CH3), 62.00 (CH3), 65.14 (CH2, C6II), 67.32 (CH, C5II), 81.51 (CH, C4I), 82.37 (CH, C4II), 83.04 
(CH, C3I), 83.22 (CH, C2II), 83.88 (CH, C2I), 84.71 (CH, C3II), 94.51 (CH, C1I), 103.82 (CH, 
68 
 
C1II), 170.32 (C), 170.60 (C); MS (ESI+-TOF): m/z (%) 475 [(M + Na)+, 100]; HRMS (ESI+-TOF): 
m/z [M + Na]+ calcd for C19H32NaO12 475.1791; found 475.1793. Anal. calcd for C19H32O12: C, 
50.44; H, 7.13. Found: C, 50.16; H, 7.21. Compound 43: colorless oil, [D]D +43.8 (c 0.820, CHCl3); 
IR (film): 3520, 2933, 1745, 1456, 1369, 1107, 1081, 1055 cm±1; 1H NMR (500 MHz, CDCl3): G 
2.05 (s, 3H), 3.05 (dd, J = 9.1, 7.6 Hz, 1H, H2II), 3.29 (ddd, J = 9.8, 3.0, 3.0 Hz, 1H, H5II), 3.34 
(dd, J = 9.0, 9.0 Hz, 1H, H3II), 3.47 (s, 3H), 3.52 (s, 3H), 3.56 (s, 3H), 3.58 (s, 3H), 3.61 (s, 3H), 
3.78 (dd, J = 9.5, 9.5 Hz, 1H, H4II), 3.86 (dd, J = 12.3, 2.8 Hz, 1H, H6II), 3.94 (d, J = 12.0 Hz, 1H, 
H6I), 4.09 (dd, J = 12.3, 3.2 Hz, 1H, H6II), 4.09 (d, J = 1.6 Hz, 1H, H4I), 4.18 (d, J = 7.6 Hz, 1H, 
H1II), 4.59 (d, J = 11.7 Hz, 1H, H6I), 4.69 (d, J = 6.3 Hz, 1H), 5.09 (d, J = 6.3 Hz, 1H), 5.58 (d, J 
= 2.5 Hz, 1H, H1I); 1H NMR (500 MHz, CDCl3, 1D-TOCSY, irradiation at H2II, 3.05 ppm): G 3.29 
(ddd, J = 9.9, 2.9, 2.9 Hz, 1H, H5II), 3.34 (dd, J = 9.0, 9.0 Hz, 1H, H3II), 3.78 (dd, J = 9.4, 9.4 Hz, 
1H, H4II), 3.86 (dd, J = 12.2, 3.4 Hz, 1H, H6II), 4.09 (dd, J = 12.0, 2.4 Hz, 1H, H6II), 4.18 (d, J = 
7.6 Hz, 1H, H1II); 1H NMR (500 MHz, CDCl3, 1D-TOCSY, irradiation at H1I, 5.58 ppm): G 3.62 
(m, 2H, H2I and H3I), 5.58 (d, J = 2.8 Hz, 1H, H4I); 13C NMR (125.7 MHz, CDCl3): G 21.89 (CH3), 
56.82 (CH3), 57.88 (CH3), 59.83 (CH3), 60.23 (CH3), 60.43 (CH3), 61.17 (CH2, C6II), 71.11 (CH2, 
C6I), 74.44 (CH, C4I), 74.66 (CH, C5II), 75.13 (CH, C4II), 76.40 (CH, C2I or C3I), 79.17 (CH, C2I 
or C3I), 84.11 (CH, C2II), 86.22 (CH, C3II), 92.88 (CH2), 96.45 (C, C5I), 97.16 (CH, C1I), 104.29 
(CH, C1II), 168.79 (C); MS (ESI+-TOF): m/z (%) 505 [(M + Na)+, 100]; HRMS (ESI+-TOF): m/z 
[M + Na]+ calcd for C20H34NaO13 505.1897; found 505.1905. Anal. calcd for C20H34O13: C, 49.79; 
H, 7.10. Found: C, 49.46; H, 7.15. 
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